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Abstract 
Viral infections account for over 13 millions deaths per year.  Antiviral drugs and vaccines 
are the most effective method to treat viral diseases.  Antiviral compounds have revolutionized 
the treatment of AIDS, and reduced the mortality rate.  However, this disease still causes a large 
number of deaths in developing countries that lack these types of drugs.  Vaccination is the most 
effective method to treat viral disease, vaccines prevent around 2.5 millions deaths per year.  
Vaccines are not able to offer full coverage due to high operational costs in the manufacturing 
processes.  Although vaccines have saved millions of lives, conventional vaccines often offer 
reactogenic effects.  New technologies have been created to eliminate the undesired side effects.  
However, new vaccines are less immunogenic and adjuvants such as vaccine delivery vehicles 
are required. 
This work focuses on the discovery of new natural antivirals that can reduce the high cost 
and side effects of synthetic drugs.  We discovered that two osmolytes, trimethylamine N-oxide 
(TMAO) and glycine reduce the infectivity of a model virus, porcine parvovirus (PPV), by 4 LRV 
(99.99%), likely by disruption of capsid assembly.  These osmolytes have the potential to be used 
as drugs, since they showed antiviral activity after 20 h.  We have also focused on improving 
current vaccine manufacturing processes that will allow fast, effective and economical vaccines to 
be produced worldwide.  We propose virus flocculation in osmolytes followed by microfiltration as 
an economical alternative for vaccine manufacturing.  Osmolytes are able to specifically 
flocculate hydrophobic virus particles by depleting a hydration layer around the particles and 
subsequently cause virus aggregation.  The osmolyte mannitol was able to flocculate virus 
particles, and demonstrate a high virus removal, 81% for PPV and 98.1% for Sindbis virus 
(SVHR).  Virus flocculation with mannitol, followed by microfiltration could be used as a platform 
process for virus purification.  Finally, we perform biocompatibility studies on soft-templated 
mesoporous carbon materials with the aim of using these materials as vaccine delivery vehicles.  
We discovered that these materials are biocompatible, and the degree of biocompatibility is within 
the range of other biomaterials currently employed in biomedical applications. 
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Chapter 1 
Introduction and overview   
20?
1.1. Introduction 
Over the last century, viral diseases such as acquired immune deficiency syndrome 
(AIDS), influenza, poliomyelitis (polio), and smallpox have affected millions of people.  The most 
effective methods to combat viral infections are with antiviral drugs or vaccines.  Synthetic 
antiviral drugs (i.e antiretrovirals) for AIDS have reduced the mortality rate by 40% from 1998 to 
2013 [1].  However, the disease still causes a large number of deaths in nations that lack of these 
types of drugs [2].  The World Heath Organization (WHO) projects an increase in mortality of 7% 
from 2015 to 2030 [3].  The discovery of new, novel and natural antiviral compounds could be 
used to treat several viral diseases and reduce the high cost and severe side effects of synthetic 
antiviral compounds.  In this study, our aim was to use natural antiviral compounds to reduce the 
infectivity of viruses.  
Vaccines are the most successful method to control and eradicate viral diseases.  
Smallpox was one the most devastating disease to humans during the past century [4] with 300-
500 millions deaths in the 20th century [5].  The virus was eradicated in 1980 following a global 
immunization campaign led by the WHO [6].  Polio is a crippling and potentially fatal infectious 
disease that does not have a cure and has taken the lives of millions of people [7].  The polio 
vaccine was discovered in 1955 [8], and thanks to its wide spread acceptance, the WHO declared 
the virus eradicated from the Americas and Europe in 1996 [9].  However, with 293 cases of polio 
being reported in 2013 in Pakistan, Afghanistan, Nigeria and Somalia [10], there is still more work 
to be done to duplicate the results that vaccination had on smallpox.  Eradication of polio will 
require less expensive vaccines and a concerted effort for distribution.  We have focused on 
improving current vaccine manufacturing processes that will allow fast, effective and economical 
vaccines to be produced for countries around the world.  Developing and emerging economy 
countries are starting to developed their own vaccines [11], inexpensive manufacturing processes 
will allow all nations to have access to vaccines.  In this work, our aim was to use virus 
flocculation followed by microfiltration as an economical alternative for vaccine manufacturing. 
Vaccines not only need to induce a specific immune response, they also need to be safe 
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[12].  Conventional vaccines often have reactogenic effects.  New technologies are safer and less 
reactogenic than conventional vaccines, but they are also less immunogenic [13-16].  In order to 
improve the immune responses in new technologies, vaccines require boosting agents called 
adjuvants.  Adjuvants such as vaccine delivery vehicles can be used to encapsulate or surround 
the vaccine formulation [13, 17, 18].  These vehicles are able to target the immune cells and 
incorporate an adequate dose, so that booster doses are not necessary [17, 19].  In this work, we 
performed biocompatibility studies on soft-templated mesoporous carbon materials with the aim 
of using these materials as vaccine delivery vehicles. 
1.2. Overview 
In the studies covered in this dissertation, we worked with osmolytes as antiviral 
compounds and virus flocculants for vaccine manufacturing.  We also worked with soft-templated 
mesoporous carbon materials, as future candidates for vaccine delivery vehicles.  Osmolytes are 
natural compounds found in cells, and their main function is to stabilize intracellular proteins 
against environmental stress and maintain cell volume.  They achieve these functions by 
preferential interactions with water molecules.  In this study we proposed to use osmolytes as 
antiviral compound and as virus flocculants. 
Soft-templated mesoporous carbon material is a new type of biomaterial.  They are made 
through a soft template method, which includes the self-assembly of surfactant micelles into a 
carbon precursor matrix.  Soft-templated-mesoporous carbon material are of great interest in 
different applications, such as separations, catalysis and energy storage, due to their large pore 
accessibility and the tunability of the pore structure.  In this work, we proposed that soft-templated 
mesoporous carbon materials can be used for another application, future vehicles for vaccine 
delivery. 
This dissertation begins with Chapter 2, where we will discuss the current knowledge of 
the interaction of osmolytes and soft-templated mesoporous carbons with biological materials.  In 
the first part of the chapter, we will discuss the differences and advantages of natural antiviral 
compounds over synthetic compounds.  In the second part of the chapter, we will discuss the 
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upstream processes (USP) and downstream processes (DSP) of the vaccine manufacturing 
processes.  We focus on the DSP, since high costs of production are connected to the main units 
operations that are used in this stage.  We will discuss the limitation of current unit operations and 
propose alternative unit operations for virus purification.  Towards the end of the chapter we will 
discuss the benefits of vaccine delivery vehicles and the different types of vehicles, including soft-
templated mesoporous carbons. 
In Chapter 3, we demonstrate that two osmolytes, glycine and trimethylamine N-oxide 
(TMAO) have the ability to disrupt the virus infection cycle of a model virus, porcine parvovirus 
(PPV).  Glycine and TMAO reduce the infectivity of PPV by 4 logs (99.99%).  We believe that 
these two osmolytes disrupt the assembly of the PPV capsid by stabilizing capsid proteins and 
preventing them from assembling.  The advantage of these osmolytes is that they can be applied 
post-infection, since they disrupt late stages in the virus infection cycle.  This work has been 
published in the Journal of Antiviral Research. 
We also use osmolytes with another purpose, as flocculants for virus purification.  We 
took advantage of the fact that osmolytes change the water structure near proteins to induce a 
preferential flocculation.  In Chapters 4 & 5, a variety of different types of osmolytes, including 
sugars, sugar alcohols and amino acids, were found to flocculate the non-enveloped virus PPV 
and the enveloped Sindbis virus (SVHR), and demonstrate a high percent removal with a 0.2 ?m 
filter.  One of our best osmolytes, mannitol at 0.3 M, was able to achieve 98% for SVHR and 81% 
for PPV.  Microfiltration (0.1 to 10 ?m), which is usually for bacterial removal; will very likely 
reduce costs as compared to typical ultrafiltration (0.01 to 0.1 ?m) used for virus removal since a 
large pore-size filter would increase the flux and decrease the transmembrane pressure, as well 
as the high costs of membrane materials.  Virus flocculation followed by microfiltration could be 
used as a global method for virus purification for enveloped and non-enveloped viruses, and 
could replace current expensive unit operations.  The findings on PPV flocculation have been 
published in the Journal of Biotechnology and the discoveries on SHRV flocculation are being 
prepared for publication.  
Chapter 6 focuses on the biocompatibility studies of soft-template mesoporous carbon 
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materials.  ???????? studies showed that soft-templated mesoporous carbon materials are not toxic, 
are biocompatible with mammalian cells, and the degree of biocompatibility is within the range or 
higher than other biomaterials currently employed in biomedical applications.  These tests are the 
first step in material biocompatibility before advancing to animal testing and clinical trials.  Based 
on our biocompatibility results, we propose that soft-templated mesoporous carbon materials 
could be used as vaccine delivery vehicles.  The material in this chapter has been published in 
the Journal of ACS Applied Materials & Interfaces.   
Finally, Chapter 7 outlines the conclusions of the research presented in this dissertation 
and discusses the future direction of the research.  
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Chapter 2  
Literature review   
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2.1. Literature review 
Since the beginning of humankind viral infections have taken the life of millions of people.  
The number of people who have died from viral diseases exceed the number of deaths caused by 
war and all other diseases combined [1].  In an effort to understand and cure viral diseases, 
scientists have studied the structure and function of different viruses.  The knowledge that we 
have gained in medical virology has led to the discovery of treatments to combat viral infections: 
antiviral drugs and vaccines.  Antiviral drugs, such as Zovirax ® (acyclovir), which inhibit the 
infectivity of the herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2), Epivir ® (lamivudine), 
which reduce the infectivity of hepatitis B virus (HBV), and Norvir ® (ritonavir), which interfere with 
the replication of the human immunodeficiency virus (HIV), have improved the quality of life of 
millions of people affected with these viral infections [2].  In addition to antiviral drugs, viral 
vaccines have been used to control yellow fever, measles, and mumps and have even eradicated 
smallpox and polio [3].  However, some viral diseases, such as dengue fever, and ebola 
hemorrhagic fever lack a vaccine or drug against infection.  Treatment of these diseases is 
primarily focused on relieving the symptoms [4, 5].  The lack of effective vaccines can be 
attributed to the inability of vaccine candidates to evoke an appropriate immune response and to 
the high costs involved in the manufacturing process [6, 7].  An improvement in current 
manufacturing process and vaccine delivery systems is needed in order to achieve a highly pure 
product and to induce a strong immune response against the viral antigen. 
2.2. Viruses and vaccines 
Virus particles are composed of genetic material (either DNA or RNA) and surrounded by 
multiple copies of identical protein subunits, which form the capsid of the virus.  The subunits can 
be arranged in two types of capsid structure.  One type shows helical symmetry and the other 
type shows icosahedral symmetry [8].  Some viruses possess a lipid bilayer that surrounds the 
capsid, and they are known as enveloped viruses.  The lipid bilayer is obtained after the virus is 
released through the cellular membrane.  Other viruses, which are known as non-enveloped 
viruses, do not possess this lipid bilayer; the capsid proteins assemble into a strong shell that 
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protects the genetic material [9].  Diseases caused by enveloped viruses include AIDS (caused 
by HIV) and ebola hemorrhagic fever (Ebola virus (EBOV)).  There is no cure or vaccine available 
for these types of virus infections, and contraction of them can be deadly.  Diseases caused by 
non-enveloped viruses include the common cold and acute gastroenteritis, most commonly 
caused by the rhinovirus (RHV) and the norovirus, respectively.  These viruses are rarely deadly, 
as is common for non-enveloped viruses.  However, these types of virus infections can be fatal to 
young children and immunocompromised patients [10-12].  Consequently there is still a need for 
the discovery of antiviral compounds and vaccines that can fight a variety of virus infections, 
which include enveloped and non-enveloped viruses. 
Viral vaccines are the most effective method to prevent viral infections [13].  Currently, 
vaccines prevent around 2.5 millions deaths per year [14].  Edward Jenner created the first 
vaccine to become available in the 1790s.  He found that the infection of cowpox protected 
humans from the smallpox infection [15, 16].  After the smallpox vaccine, several other vaccines 
became available, including the rabies vaccine in 1885, the yellow fever vaccine in 1935 and the 
polio vaccine in 1962 [17].  Although effective vaccines have been developed for several viral 
diseases, there are some viral infections that have shown to be resilient to vaccine therapy, such 
as HIV, and hepatitis C virus (HCV) [18-20].  Worldwide, infectious diseases account for over 13 
million deaths every year [13].  At the end of 2013, 35 million people had HIV, 2.1 million people 
became infected and 1.5 million died for AIDS-related causes, according to the World Health 
Organization (WHO) [21].  Other viral pathogens, like adenovirus, rhinovirus, human 
herpesviruses, and all the haemorrhagic fever viruses also lack any type of vaccines [18].  
Additionally, new viruses are emerging and causing outbreaks around the word, such as severe 
acute respiratory syndrome (SARS) in 2004, influenza A H1N1 virus in 2009, and the Middle East 
respiratory syndrome (MERS) in 2012.  Millions of more lives could be saved with improved 
access to current vaccines and the creations of new vaccines. 
There are three types of vaccines licensed for use in humans: live-attenuated, inactivated 
or killed, and subunit vaccines [17, 22-24].  First-generation antiviral vaccines were made through 
live animals, like cow or rabbits [16].  In the middle of the twentieth century, virus growth was 
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adapted to cell culture.  Virologists learnt that attenuation could be achieved by several culture 
passages [16, 17, 25].  Viral vaccines, such as the oral polio vaccine in 1963, the measles 
vaccine in 1963, the mumps vaccine in 1967, and the varicella vaccine (i.e. chicken pox) in 1995 
were all made through attenuation of viruses in cell culture [26-29].  Another great discovery in 
the 20th century was that immunogenicity could be obtained if the pathogen was inactivated 
either by heat or chemical treatment [17, 25].  Vaccines, like influenza in 1936 and hepatitis A 
(HAV) in 1996, contain whole inactivated virus [30, 31].  Finally, subunit vaccines, such as HBV?
[32] and the human papilloma [33], are generated by expressing viral capsid proteins [17, 25].  
Today, several inactivated and live-attenuated vaccines are propagated through cell culture.  
Although, cell culture-derived vaccines has helped to fulfill the demand of pandemics viral 
diseases and the increment of vaccines supplies, there are still viral infections, like EBOV and 
HIV without any type of vaccines offered, likely due to the fact that viral vaccines are difficult and 
expensive to develop.  In this study, we propose to use virus flocculation with osmolytes, followed 
by microfiltration as an economical purification step in order to reduce the costs of current unit 
operations used in vaccine manufacturing.  At the same time we found out that osmolytes can 
interfere with the replication cycle of infection virus particles and can be used as potential 
candidates for antiviral compounds. 
2.3. Osmolytes 
Osmolytes are natural, organic compounds that are found in the cells of many organisms 
[34-36] and their main function is to stabilize intracellular proteins against environmental stresses, 
such as extreme temperatures or high osmotic pressure by changing the water content of the 
cells [37].  There are two types of osmolytes, protecting and denaturing osmolytes.  Protecting 
osmolytes fold proteins by structuring water and changing the water content around the protein 
backbone.  Denaturing osmolytes have the opposite effect; they unfold the proteins by binding 
directly to the protein backbone (Figure 2.1) [38].  A balance between protecting and denaturing 
osmolytes assists in the delicate equilibrium needed for protein stabilization in nature [39]. 
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Figure 2.1.  Protecting and denaturing osmolytes.  Protecting osmolytes have the ability to fold 
proteins, by structuring water.  Denaturing osmolytes have the ability to bind to the backbone of 
proteins, leading to protein unfolding. 
?
The behavior of protecting and denaturing osmolytes with regard to proteins in solution 
can be explained with the preferential interaction theory.  Protecting osmolytes have attractive 
interactions (? ?) with water molecules, but unfavorable interactions with the protein backbone 
(???).  The preferential interaction between the protein backbone and water molecules is known 
as the preferential exclusion of solute.  The preferential exclusion of solute orders water 
molecules in a thermodynamically unfavorable way, which causes protein folding in order to 
reduce the increase in entropy [40].  The interaction between denaturing osmolytes and protein 
backbone is known as a favorable preferential interaction [37].  Denaturing osmolytes appear to 
bind to the protein backbone by hydrogen bonds and they have repulsive interactions with water 
molecules [40].  
The phenomena of protecting and denaturing osmolytes in solution with proteins have 
also been explained with a solvophobic/solvophilic effect.  This theory suggests that the 
preferential exclusion of the protecting osmolyte can be explained as a solvophobia effect of the 
protein surface for the hydrated osmolyte as compared to water [37].  On the other hand, the 
favorable preferential interaction of denaturing osmolytes with water molecules can be explained 
as a solvophilic effect, since interactions between the denaturing osmolyte and proteins are more 
favorable than interactions between water and proteins [37]. 
Scientists have also measured the transfer free energy (??????????) in order to understand 
the interactions between the protein backbone and osmolytes. Street and coworkers measured 
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osmolytes 
Water 
Protein 
Osmolyte 
Denaturing 
osmolytes 
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the free energy change of the backbone of the protein from water to 1 M osmolyte solutions [38].  
They showed that protecting osmolytes have an increased change in the Gibbs free energy.  This 
is likely because protecting osmolytes interact unfavorably with the protein, resulting in a 
preferential depletion from the protein backbone.  On the other hand, denaturing osmolytes 
decreased the change in Gibbs free energy by interacting favorably with the unfolded state of the 
proteins, resulting in preferential binding of the osmolyte to the protein backbone [38].  It is likely 
that the protein backbone transfer free energy primarily determines if an osmolyte stabilizes or 
destabilizes a protein in solution. 
We would like to take advantage of the behavior of protecting osmolytes in protein 
solutions and also of the fact that virus capsids are made of proteins.  We propose to use 
osmolytes as antiviral compounds against viruses (Chapter 3), and as flocculants in order to 
improve virus purification techniques for vaccine production (Chapter 4 & 5).  Protecting 
osmolytes have the ability to rearrange water molecules near the surface of the protein and to be 
excluded from the protein surface.  They can fold and consequently stabilize the protein.  
Protecting osmolytes are potential candidates for antiviral compounds, since they could 
potentially stabilize viral capsid proteins and prevent them from assembling into infectious virus 
particles.  On the other hand, protecting osmolytes can be used as flocculants.  The osmolyte 
flocculants are able to deplete a hydration layer around the hydrophobic virus particles and thus 
cause virus aggregation.  As osmolyte flocculant concentration is increased, more water 
molecules are removed from the capsid virus proteins, causing virus aggregation and flocculation.  
Osmolytes flocculation has many advantages.  Osmolytes are often used as excipients to 
stabilize protein final formulations, and therefore this method only adds compounds that are 
already known to be safe for injection.  Flocculation allows for larger pore-sized membranes to be 
used during purification, which decreases costs by lowering transmembrane pressures and 
reducing fouling. 
2.4. Antiviral Compounds 
Antiviral compounds have revolutionized the treatment of some viral infections that 
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cannot be controlled with vaccines, such as, HCV HIV, and HSV 1 & 2 [41, 42].  The first antiviral 
compound, acyclovir, was released in the 1970s.  Scientists found that the compound could 
inhibit DNA replication of HSV-1 & 2 at concentrations that did not affect cellular DNA synthesis 
[43, 44].  During the last two decades, many antiviral compounds have been approved; most of 
them are antiretrovirals that are used to treat HIV infections [2, 45, 46], allowing people to live 
longer with the virus.  Antiviral compounds are classified either into synthetic or natural.  The aim 
in the development of effective antiviral compounds is to find new antiviral compounds, which can 
target the virus or its replication, without interfering with any metabolic cellular process [19].  
Molecular biology has greatly accelerated our knowledge in understanding the virus replication 
cycle and will continue to aid in the discovery of new biological targets for antiviral compounds. 
2.4.1. Synthetic antiviral compounds 
Many synthetic antiviral drugs are currently approved for clinical use in the treatment of 
viral infections caused by HIV, HBV, HCV, HSV 1 & 2, and influenza virus type A & B (IFV-A & B) 
[41].  Viruses share similar stages in their replication cycle (see Figure 2.2), starting with 
adsorption and penetration into the host cells.  Then, the genetic material is uncoated inside the 
cell.  Small viruses use the host cell’s replication machinery to produce nucleic acids and viral 
proteins, whereas larger viruses have these proteins encoded in their genome.  Then virus 
particles are assembled and the virus progeny are released from the cell [19, 47]. 
Synthetic compounds that have been approved have been found to inhibit virus infection 
by different mechanisms of actions (Table 2.1 & Figure 2.2).  The first stage in the virus infection 
cycle involves attachment of virus to host cells.  After adsorption, virus particles can enter the 
cells either by fusion or endocytosis.  Enfuvirtide and palivizumaba have been approved as virus-
cell fusion inhibitor against HIV and respiratory syncytial virus (RSV) infections, respectively [48, 
49].  Uncoating is an important step in the virus replication cycle, since the genetic material of the 
virus is release inside of the cells.  Antiviral compounds that interfere with this stage have been 
found against the IFV-A virus [50].   
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Figure 2.2.  Virus infection cycle.  The virus infection cycle starts with virus attachment to 
susceptible cells, followed by penetration and adsorption.  In the uncoating step, the genetic 
material is released inside of the cells.  Small viruses use the host cell’s replication machinery to 
produce nucleic acids and viral proteins, whereas larger viruses have these proteins encoded in 
their genome.  The virus particles are then assembled and the new virions are released out of the 
cell. Image adapted from [51]. 
 
Numerous viruses synthesize their own viral enzymes, such as DNA polymerase, RNA 
polymerase and retroviruses require reverse transcriptase (RT) to synthesize their nucleic acids 
[2].  Antiviral compounds that target these enzymes are of great interest, since these 
polymerases are required for the replication of the virus and are unique to viruses [52]. 
Nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors 
(NtRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are viral polymerase 
inhibitors approved for HIV infections [46].  NRTIs and NtRTIs are known as competitive subtract 
inhibitors.  They block the RT activity, by acting as chain terminators and preventing completion 
of viral DNA synthesis [41].  NNRTIs have a different mode of action, they bind to an allosteric 
pocket in the p66 subunit of the RT and prevent DNA synthesis by a non-competitive mechanism 
of action [2].  HIV viral polymerase inhibitors are used in different combinations and doses to 
suppress the HIV infection and stop the progression of the disease.  Protease inhibitors, such as 
ritonavir against HIV and telaprevir against HCV are drugs used to block viral protease activity [2, 
18, 41, 46, 53].  
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Table 2.1.  Synthetic antiviral compounds approved in the market 
Antiviral drug Target virus Capsid Mechanism of action Reference 
Enfuvirtide HIV E Entry inhibitor [2, 41, 48] 
Maraviroc HIV E Entry inhibitor [2, 54] 
Palivizumaba RSV E Entry inhibitor [2, 49] 
Amantadine IFV-A  E Uncoating inhibitors [2, 41, 50] 
Rimantadine IFV-A E Uncoating inhibitors [2, 41, 50] 
Acyclovir HSV-1 & 2 E DNA polymerase inhibitors [2, 18, 41, 55]  
Famciclovir HSV-1 & 2 E DNA polymerase inhibitors [2, 18, 41, 55] 
Valaciclovir HSV-1 & 2 E DNA polymerase inhibitors [2, 18, 41, 55] 
Ganciclovir CMV E DNA polymerase inhibitors [2, 18, 41] 
Valganciclovir CMV E DNA polymerase inhibitors [2, 18, 41] 
Brivudine HSV-1 & 2 E DNA polymerase inhibitors [2, 18, 41] 
Foscarnet HSV-1 & 2 E DNA polymerase inhibitors [2, 18, 41] 
Penciclovir HSV-1 & 2 E DNA polymerase inhibitors [18, 41] 
Cidofovir CMV E DNA polymerase inhibitors [2, 18, 41] 
Trifluridine HSV-1 & 2 E Disrupt DNA replication [41] 
Idoxuridine HSV-1 & 2 E Disrupt DNA replication [41] 
Fomivirsen CMV E Block translation of mRNA [41] 
Abacavir HIV E NRTIs [2, 18, 41, 46] 
Didanosine HIV E NRTIs [2, 18, 41, 46] 
Emtricitabine HIV E NRTIs [2, 41, 46] 
Stavudine HIV E NRTIs [2, 18, 41, 46] 
Zalcitabine HIV E NRTIs [2, 18, 41, 46] 
Zidovudine HIV E NRTIs [2, 18, 41, 46] 
Lamivudine HIV & HBV E NRTIs [2, 18, 41, 46] 
Entecavir HBV E NRTIs [2] 
Telbivudine HBV E NRTIs [2] 
Adefovir HBV E NRTIs [2] 
Tenofovir HIV & HBV E NRTIs [2, 18, 41, 46] 
Efavirenz HIV E NNRTIs [2, 18, 41, 46] 
Etravirine HIV E NNRTIs [2, 46] 
Delavirdine HIV E NNRTIs [2, 18, 41, 46] 
Nevirapine HIV E NNRTIs [2, 18, 41, 46] 
Rilpivirine HIV E NNRTIs [2, 46] 
Ribavirin HCV & RSV E RNA inhibitor [2, 18, 41] 
Raltegravir HIV E Integrase inhibitor [2, 46] 
Amprenavir HIV E Protease inhibitors [2, 18, 41, 46] 
Atazanavir HIV E Protease inhibitors [2, 41, 46] 
Fosamprenavir HIV E Protease inhibitors [2, 46] 
Indinavir HIV E Protease inhibitors [2, 18, 41, 46] 
Lopinavir HIV E Protease inhibitors [2, 18, 41, 46] 
Nelfinavir HIV E Protease inhibitors [2, 18, 41, 46] 
Ritonavir HIV E Protease inhibitors [2, 18, 41, 46] 
Saquinavir HIV E Protease inhibitors [2, 18, 41, 46] 
Darunavir HIV E Protease inhibitors [2, 46] 
Tipranavir HIV E Protease inhibitors [2, 46] 
Boceprevir HCV E Protease inhibitors [2, 56] 
Telaprevir HCV E Protease inhibitors [2, 53] 
Oseltamivir IFV-A & B E Neuraminidase inhibitors [2, 18, 41, 57] 
Peramivir IFV-A & B E Neuraminidase inhibitors [2] 
Zanamivir IFV-A & B E Neuraminidase inhibitors [2, 18, 41, 58] 
 
Viral proteases are important in the replication of the virus, since they catalyize the 
process of viral polyproteins production and in the processing of making precapsids [2].  The last 
step in the virus infection cycle is release of virus progeny out of the cells.  Some compounds 
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have been found to inhibit this stage, by acting on the viral proteins involved in this step.  
Oseltamivir and Zanamivir inhibit the influenza neuraminidase activity, protein that enables the 
virus to be released from the cells [41].  Both of them have been approved for the treatment of 
IFV-A & B infection [57, 58].   
Although synthetic antiviral compounds have been shown to treat viral diseases, some of 
these antivirals have been shown to present severe side effects.  Acyclovir, which is one of the 
most commonly used medications to treat HSV 1 & 2, causes confusion and ataxia [59] and also 
kidney failure [60].  The main side effect of ribavirin, a drug used to treat HCV, is haemolytic 
anemia [61].  NRTIs have revolutionized the treatment of AIDS, however, high active doses 
coincide with mitochondrial toxicity, which can lead to serious sides effects such as hepatic failure 
and lactic acidosis [62].  The ineffectiveness of current treatments for several viral diseases and 
the fast grow of new drug-resistant viral strains have pressed researchers for the discovery of 
new, natural antiviral compounds [20].  Researchers are now interested in natural products, which 
can often ameliorate the severe side effects of synthetic drugs [19].  Such natural products can 
be obtained more easily [63]; consequently, these products are inexpensive as compared to 
synthetic compounds [64].  Moreover, viruses are becoming resistant to current synthetic drugs, 
and new treatments are required [19].  Natural products have been shown great promise in 
medicine, approximately 40% of the most commonly used medicines contains compounds 
derived from natural sources, using either the isolated substance or a synthetic version [64].  
2.4.2. Natural antiviral compounds 
The complexity of many synthetic compounds and the lack of accessibility in developing 
countries have created a massive interest by the academia and public organizations in natural 
antiviral compounds [65].  Since the beginning of humankind, plants extracts and essential oils 
have been widely used in traditional medicine to treat different types of diseases [66-69].  Many 
plants have been reported to have antiviral activity [19, 68, 70, 71] and some of them have been 
used to treat viral diseases in animals and humans [72, 73].  However there are innumerable 
compounds from different plants waiting to be evaluated and exploited for the therapeutic effect 
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against different types of viruses [19].  Natural products are promising candidates for novel 
antiviral compounds.  Because they come from natural sources, they offer structural diversity and 
biochemical specificity.  Natural antiviral products can be classified either as plant extracts or as 
isolated substances.  The extracts are unpurified samples where the antiviral compounds are not 
known and the isolated compounds are purified compounds where we know the exact activity of 
that compound.  Isolated compounds can then be made from purification of the plant extract or 
synthetically to become a commercial product. 
2.4.2.1. Natural antiviral extracts  
Recent ???????? studies on antiviral compounds have shown that plant extracts and 
essential oils exhibit antiviral activity against certain types of viruses (Table 2.2).  Several antiviral 
essential oils alter initial stages of the virus infection cycle (Figure 2.2).  Inactivation of herpes 
simplex virus (HSV) particles prior to attachment was seen with essential oil from star anise which 
reduced the infectivity of HSV-1 by 99% [74], artemisa oil, which reduced the infectivity of HSV-1 
& 2 by 80% [75], the essential oils derived from ginger, thyme, hyssop, and sandalwood that 
reduced the titers of HSV-1 by 99% [76], manuka essential oil that reduced the infectivity of HSV-
1 & 2 by 99.5% and 98.9%, respectively [77], the Australian tea tree oil (TTO) reduced the 
infectivity of HSV-1 & 2 by 98.2% and 93.0% respectively [78].  Essential oils such as clove oil, 
oregano, and sataria, were able to inhibit the adsorption of nororovirus surrogates, such as feline 
calicivirus (FCV) and murine norovirus (MNV) by inactivating the virus capsid [79, 80].  Oregano 
and clove oils essential oils were also able to lyse the lipid envelope of HSV-1 and Newcastle 
disease virus, strain LaSota (NDV-LS) [81].  Essential oils were able to prevent virus attachment 
and adsorption, probably by disruption of virus capsids and viral envelopes.  
Natural extracts of phyllanthus orbicularis, quillaja saponaria and chamomile were able to 
inactivate HSV particles and inhibit virus attachment [82-85].  Extracts of ribes nigrum L, and 
quillaja saponaria, were able to prevent virus adsorption of other types of enveloped viruses, such 
as IFV-A & B and HIV-1 & 2, respectively [83, 86].  Plant extracts have also been able to inhibit 
late stages in the virus infection cycle of enveloped viruses.  Extracts of scutellaria baicalensis, 
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eugenia caryophyllus, lavender and sage were found to disrupt virus replication of dengue virus 
(DENV), HSV-1 & 2, HSV-1 and HSV-2, respectively [84, 87, 88].  Non-enveloped viruses were 
also affected by natural extracts.  Extracts from raoulia australis and quillaja saponaria, blocked 
virus attachment of RHV and rotavirus, respectively, probably by interacting with the virus particle 
[89, 90].  Fruits extracts or juices (strawberry, grape, apple, and cranberries) inhibit virus 
adsorption of non-enveloped viruses [91-100].  Extracts for different types of plants were able to 
inhibit the infectivity of enveloped and non-enveloped at different stages in the virus infection 
cycle.  However, further studies are required with plant extracts and essential oils since the 
identification and isolation of the active compound is required for the production of the antiviral 
drug. 
Table 2.2.  Essential oil and plant extracts as antiviral compounds 
Essential oils Virus C Mechanism Reference
Star anise  HSV-1  E Entry inhibitor (attachment) [74] 
Artemisia  HSV-1 & 2 E Entry inhibitor (attachment) [75] 
Ginger HSV-1 E Entry inhibitor (attachment) [76] 
Thyme HSV-1  E Entry inhibitor (attachment) [76] 
Hyssop HSV-1  E Entry inhibitor (attachment) [76] 
Sandalwood HSV-1  E Entry inhibitor (attachment) [76] 
Manuka HSV-1 & 2 E Entry inhibitor (attachment) [77] 
TTO HSV-1 & 2 E Entry inhibitor (attachment) [78] 
Clove  FCV, MNV N Entry inhibitor (attachment) [79] 
Oregano  FCV, MNV N Entry inhibitor (attachment) [79] 
Zataria  FCV, MNV N Entry inhibitor (attachment) [79] 
Oregano MNV N Entry inhibitor (attachment) [80] 
Oregano & clove  HSV-1 & NDV-LS E Entry inhibitor (attachment) [81] 
Plant extracts Virus C Mechanism Reference 
Ph. orbicularis  HSV-1 & 2 E Entry inhibitor (attachment) [82] 
Quillaja saponaria  HIV-1 & 2 E Entry inhibitor (attachment) [83] 
Chamomile HSV-1 E Entry inhibitor (adsorption) [84] 
Melissa officinalis HSV-1 E Entry inhibitor (adsorption) [85] 
Ribes nigrum L IFV-A & B E Entry inhibitor (adsorption) [86] 
Quillaja saponaria  HIV-1 & 2 E Entry inhibitor (attachment) [83] 
S. baicalensis DENV E Replication inhibitor [87] 
E. caryophyllus HSV-1 & 2 E Replication inhibitor [88] 
Lavender HSV-1 E Replication inhibitor [84] 
Sage HSV-2 E Replication inhibitor [84] 
Raoulia australis RHV N Entry inhibitor (attachment) [89] 
Quillaja saponaria  Rotavirus N Entry inhibitor (attachment) [90] 
Straberry extract PoV N Entry inhibitor (attachment) [94] 
Cranberry extracts Reovirus N Entry inhibitor (attachment) [97] 
Cranberry juice Rotavirus N Entry inhibitor (attachment) [91, 92] 
Grape seed extract FCV, MNV N Entry inhibitor (attachment) [98]  
Cranberry juice FCV, MNV N Entry inhibitor (attachment) [99] 
Pomegranate juice FCV, MNV N Entry inhibitor (attachment) [93] 
Grape juice PoV N Entry inhibitor (attachment) [95, 96] 
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2.4.2.2. Isolated natural antiviral compounds  
The main aim in the development of any antiviral drugs is the identification and isolation 
of the active ingredient.  Specific biochemical substances such as polyphenols, polysaccharides, 
peptides, proteins and other found in natural sources have been identified and found to reduce 
the infectivity of certain types of viruses (Table 2.3).  Catechins from black and green tea have 
been shown to have antiviral activity against enveloped and non-enveloped viruses.  
Epigallocatechin gallate (EGCG) is the most abundant catechin and has shown antiviral activity 
against several viruses.  EGCG prevents attachment of HCV, disrupts the envelope of HSV-1 & 
2, disrupts replication of IFV-A & B, inhibits HBV DNA synthesis, and suppresses replication of 
the enterovirus 71 (EV71) [101-107].  Theaflavin-3,3-digallate (TF-3) derivate from black tea was 
found to inactivate the viral envelope of HSV-1 & 2 and IFV-A & B [108-110].  Several tea 
polyphenols have been found to inhibit IFV-A & B adsorption [111-113].  Polyphenols found in 
plant and fruits have also shown antiviral effects.  The flavonoid, 5,7,4'-trihydroxy-8-
methoxyflavone (F36) inhibit the fusion of viral envelopes with the endosome/lysosome 
membrane, which occurs at the early stages of the virus infection cycle [114, 115].  Resveratrol 
(RV) has been shown to inhibit virus replication of enveloped viruses, such as varicella zoster 
virus (VZV) and IFV-A [116, 117].  Polyphenols in pomegranate, such as ellagic acid, caffeic acid, 
luteolin, and punicalagin block replication of virus RNA of IFV-A [118].  In general, polyphenols 
work by disruption of the early stages in the virus infection cycle of enveloped viruses, with only 
few exceptions.   
Polysaccharides isolated from fungi and plants have shown antiviral activity.  
Polysaccharides from agaricus brasiliensis a species of mushrooms inhibit the attachment of 
poliovirus (PoV) into the host cells [119].  Yellow fever virus (YFV) envelope was disrupted by 
polysaccharides found in the lichen, parmelia perlata [120].  Inhibition of HSV-1 & 2 adsorption 
was achieved with polysaccharides found in the plant, sargassum patens [121, 122].  Isolated 
polysaccharides from rhizophora mucronata were found to bind to HIV particles and inhibit virus 
attachment [123].  Finally polysaccharides found in nothogenia fastigiata have shown inhibition of 
39 
?
human cytomegalovirus (HCMV) adsorption [124].  Polysaccharides were found to disrupt early 
stages in the virus infection cycle of enveloped viruses and non-enveloped virus.   
Other natural compounds such as peptides and osmolytes have shown antiviral 
properties against non-enveloped viruses.  A peptide isolated from Enterococcus mundtii was 
found to disrupt the virus capsid of PoV [125], while osmolytes were able to inhibit the assembly 
of the porcine parvovirus (PPV) virus capsid [126].  The advantage of natural compounds that 
disrupt virus replication is that they can be applied post-infection, which increase their potential 
therapeutic drugs.  The majority of the antiviral compounds found in the literature present antiviral 
activity against enveloped viruses, due the fact the envelope capsid are easier to inactivate.  The 
main advantage of antiviral compounds is that they can reduce the high costs of synthetic 
antiviral compounds.  Several compounds have been isolated from natural sources and they have 
shown antiviral activity against different types of viruses, demonstrating that natural antiviral 
compounds could be used as new treatments for viral infections.  All the studies presented in this 
section have been done ????????, if people are treated with these substances, large quantities are 
needed and more studies needs to be done in order to determine the side effects. 
Table 2.3.  Polyphenols, polysaccharides and other compounds as antivirals 
Polyphenols Virus Capsid Mechanism Reference
EGCG HCV  E Entry inhibitor (attachment) [101, 102] 
 HSV-1 & 2 E Entry inhibitor (attachment) [103] 
 IFV-A & B E Replication inhibitor [104, 105] 
 HBV E Replication inhibitor [107] 
 EV71 N Replication inhibitor [106] 
 IFV-A & B E Entry inhibitor (adsorption) [113] 
TF-3 HSV-1 & 2 E Entry inhibitor (attachment) [108, 109] 
 IFV-A & B E Entry inhibitor (attachment) [110] 
 IFV-A & B E Entry inhibitor (adsorption) [111, 112] 
F36 IFV-A & B E Entry inhibitor (attachment) [114, 115] 
RV VZV E Replication inhibitor [117] 
 IFV-A E Replication inhibitor [116] 
Ellagic acid IFV-A E Replication inhibitor [118] 
Polysacharides from Virus Capsid Mechanism Reference 
Agaricus brasiliensis PoV N Entry inhibitor (attachment) [119] 
Parmelia perlata YFV E Entry inhibitor (attachment) [120] 
Sargassum patens HSV-1 & 2 E Entry inhibitor (adsorption) [121, 122] 
Rhizophora mucronata HIV E Entry inhibitor (attachment) [123]
Nothogenia fastigiata HCMV E Entry inhibitor (adsorption) [124] 
Others Virus Capsid Mechanism Reference
Peptide from 
Enterococcus mundtii PoV N 
 
Replication inhibitor [125] 
Osmolytes PPV N Replication inhibitor [126] 
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2.5. Vaccine manufacturing 
The aim of the vaccine market is to produce and manufacture safe and effective 
vaccines.  The vaccine market presents several challenges, such as complexity in the production 
process, insufficient supply, high costs, and stringent regulatory requirements [127].  Vaccine 
production requires the use of living cells and the grow of the immunogenic agent, followed by a 
multifaceted purification process, in order to obtained the desired product [7].  The supply of 
vaccines is insufficient for industrialized, developing, and third-world countries, due the fact that 
there are too few manufacturers [17].  The biggest challenge in the vaccine industry is to reduce 
the cost of vaccine production.  Currently, pharmaceutical companies avoid the vaccine industry 
because it is economically expensive, and involves many regulatory barriers [7, 24].  The cost of 
a new vaccine is around $300 to $800 million, and pharmaceutical companies need to provide the 
cost of research and development [17].  Additionally, pharmaceutical companies do not feel 
attracted to the market since the financial investment return tends to be low and unpredictable as 
compared to other types of drugs in the areas of oncology, cardiovascular and neurodegenerative 
diseases [24, 128].  The regulatory considerations are extremely high in the vaccine market, 
since vaccines are molecules that are more difficult to characterize than any other small 
pharmaceuticals [127].  Moreover, there is not a standard platform process for vaccine 
manufacturing similar to the antibody manufacturing process, due to the fact that vaccines are 
unique molecules that require different routes of production [129].  Despite all the limitations in 
the vaccine market, the World Health Organization (WHO) reported in 2010 that the vaccine 
market growth rate was 9-15% per year, higher than the growth rate of other pharmaceuticals at 
5-7% per year [130].  The annual sales of the vaccine market were reported to be $21.7 and 
$25.3 billion in 2009 and 2010, respectively, and are projected to reach $39.5 billion in 2015 
[131].  Expansion of the medical market and reduction in costs in current process is needed in 
order to increase the access to vaccines. 
The vaccine production process is divided into upstream processes (USP) and 
downstream processes (DSP) (Figure 2.3).  The USP includes cell and virus propagation, while 
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the DSP include a variety of steps for the recovery and purification of the desired vaccine.  
Different types of DSP have been developed to purify viruses and most of them follow similar unit 
operations.  After cell culture and virus harvesting, cell lysis and clarification needs to be done in 
order to remove cells debris.  The virus is clarified by low speed centrifugation, and the 
supernatant is recovered and filtered.  Then the virus solution can be purified with centrifugation 
and filtration, or filtration and chromatography.  The final step in the DSP is the polishing step, 
which is usually done with chromatography or filtration [132-135].  The increase in USP 
production yields and harvest volumes is creating a strain on current DSP to handle the increased 
product load [23].  Moreover, the DSP account for 70% of the overall cost of any biotherapeutic 
production process [136, 137].  To satisfy the current and future market demand, an improvement 
in current DSP is needed.  
?
Figure 2.3.  Upstream and downstream processing in vaccine manufacturing. 
 
2.5.1. Upstream processes 
In the first stages of the vaccine manufacturing process, the virus is generated.  Viruses 
are grown either in primary cells (chicken eggs) or in established cell lines.  Recombinant-
vaccines can be made with an expression system, such as yeast, bacteria, or mammalian cells 
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[138].  The egg-based technology presents scale-up challenges, which include highly manual, 
bacteria contamination, slow production times, low yields and a high quantity of eggs needed 
[138, 139].  Manufacturing companies prefer cell-based vaccine manufacturing processes, since 
they offer easy scale-up, faster processing time and low risk of contamination [138, 140].  The 
parameters most relevant in USP are the design of new bioreactors or modifying exiting ones, 
optimization of current processes, and manipulations of the cell culture media [141].   
2.5.2. Downstream processes 
The DSP of biological products is affected by the impurities and contaminants, like host 
cell protein (HCP), cell debris, and host cell DNA that are generated in the USP [142, 143].  
Followed by the production of the virus particles a series of steps in the DSP are required in order 
to recovery and purify the virus from contaminants. The first steps in the DSP are cell lysis and 
clarification.  At a manufacturing level, cells are lysed by microfluidization, tangential flow filtration 
or osmotic shock [144].  Clarification is the step used to remove cell debris, particulates and 
insoluble matter after cell lysis.  This step is usually done with centrifugation, filtration, or a 
combination of both of them, either in batch or continuous mode [135, 139, 144].  After the virus 
particles have been recovered, further virus purification steps are required in order to obtain the 
final product. 
Different types of methods have been proposed for virus purification.  The first methods 
used for virus purification at small-scale were ultracentrifugation and density gradient 
centrifugation [135, 145].  However, due to the size of the equipment, these methods are difficult 
to maintain, scale-up restricted, cost-ineffective, labor-intensive, require long processing times, 
and often several impurities remain at the end of the process [144, 146].  Moreover, 
ultracentrifugation can lead to low recovery yields due to virus degradation and loss of infectivity 
[145].  Chromatography used for protein purification has been adapted to virus purification to 
overcome the limitations of ultracentrifugation.   
Chromatography is the most prevalent technology for large-scale purification of viral 
particles, since it is fast, scalable and reproducible [144, 147].  Additionally, chromatography 
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offers many advantages compared with density gradient ultracentrifugation, which include 
removal of HCPs and contaminated DNA, high yields, and faster processing times [138].  
However, purification of virus particles is a challenge due the large particle sizes, low diffusion 
and complex molecular surfaces structures [148, 149].  There is not a universal chromatography 
process that can be applied to all types of viruses.  The stationary phases used in 
chromatography are packed beds, monoliths and membranes [150].  Packed beds are 
conventional chromatographic supports that were designed for the purification of proteins and are 
not suitable for large biomolecules, such as virus particles [151].  The main disadvantage of 
conventional chromatography is that virus particles present limited diffusion into the pores of the 
resins.  Virus particles have difficulties accessing the high internal surface area of the resins [152, 
153] and as a consequence the recovery of the viral particles is low, the pressure drop is high 
due to poor pore diffusion through the bed and the time processing rates are slow [23, 132, 135].  
Monoliths and membranes allow rapid convective mass transfer, however, it is difficult to keep 
uniform properties through the membranes and the capacity of the membrane can be limited 
[153].  All of the typical chromatography modes have been utilized for virus particle purification, 
including gel filtration or size-exclusion chromatography (SEC), ion exchange chromatography 
(IEC), affinity chromatography (AC), and hydrophobic-interaction chromatography (HIC) (Figure 
2.4) [23], and all of them present limitations.   
?
Figure 2.4.  Chromatography modes.  A) Size exclusion, B) Ion exchange, C) Hydrophobic 
interaction, D) Affinity. 
 
SEC could be used with several strains of viruses, since virus binding does not occur 
during the chromatography run [135].  However, SEC cannot remove large contaminants [153], 
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presents low capacity and the matrix has poor pressure resistance [23].  IEC is the most widely 
chromatography technique used for virus purification [153].  The principle of IEC is charge- 
charge interaction between the virus and chemical groups on the matrix.  The selection of the 
right matrix depends of the isoelectric point (pI) of the virus.  This method offers high selectivity 
and is easy to scale-up [135, 153].  However, IEC cannot remove empty capsids [153], presents 
low specificity and co-elution of contaminants [23].  AC is based on highly specific interactions 
between the target molecule and ligands bound on the matrix.  AC offers high selectivity, 
reduction of contaminants, and the possibility of reducing purification steps [135, 154].  
Nevertheless, AC is not recommended for large-scale process [23], since the ligands are 
expensive.  HIC is based on interactions between the virus and hydrophobic ligands on the 
surface of the stationary phase.  The main disadvantages of HIC are low recovery and viral 
degradation due to the high concentrations of salts [144].  All the modes used in chromatography 
columns have presented several limitations that could increase the operational cost of the DSP. 
The large size differences between virus particles and typical protein contaminants 
suggest the use of filtration as an alternative for virus purification [153].  Membranes filtration 
processes are usually combined with chromatography.  Membrane-based tangential flow filtration 
(TFF) techniques, which are based on size differences, including ultrafiltration and nanofiltration, 
have shown high viral titers and high recoveries [148, 155, 156].  Additionally, membrane 
processes are very advantageous techniques due to the easy scalability and high throughput 
[148, 157].  However, the capacity of the membranes can be affected by fouling, which can occur 
by pore blocking, pore constriction, caking or a combination of all of them [158].  Fouling can lead 
to longer filtration time, high transmembrane pressure, and low flux through the membrane [23, 
136].  All of these drawbacks could increase the cost of production of DSP. 
Precipitation and flocculation followed by centrifugation or filtration has been used for 
virus purification [136].  Commonly, the additives are compounds that promote aggregation, like 
irons, salts or polymeric agents, such as poly(ethylene) glycol (PEG) [159].  Chemical flocculation 
with salts and irons, followed by microfiltration and/or ultrafiltration have been used to remove 
viruses, such as bacteriophages and ocean viruses from protein-free conditions [160-162].  Salts 
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and iron flocculants provides high virus removal of the MS2 phage, >7.4 logs and >4.0 logs, 
respectively [160-161].  However, it is likely that high salt concentrations may precipitate more 
than one protein, if the virus is in a solution containing other proteins.  PEG is a well-known 
additive, which is used to precipitate all proteins [163], although specific conditions have been 
used to selectively precipitate IgG4 from cell culture [164] and viruses bacteriophages from DNA 
and protein contaminants [165].  Appropriate processing conditions for PEG precipitation might 
lead to effective primary purification of bioproducts in large-scale process.  However, PEG 
precipitation present some disadvantages. PEG precipitation requires extended periods of 
incubation time [166] and polymer additives can interact with virus particles and form complexes 
that are difficult to dissociated [167, 168].  The aim in virus precipitation/flocculation is to improve 
process robustness; a selective, global, nontoxic, and economical precipitant/flocculants is 
desired [23].  Membrane processes and chromatography processes do not offer a general 
platform that can be used for all types of viruses [148, 169].  We propose to use virus flocculation 
with osmolytes, followed by microfiltration, as an alternative to the current manufacturing system 
[170].  The osmolyte flocculants are able to deplete a hydration layer around the virus particles 
and subsequently cause virus aggregation [170].  We hypothesize that osmolytes are better than 
salts or polymer flocculants, since they are often used as an excipient to stabilize the final 
formulation of drugs or biotherapeutics [171, 172]. 
The final steps in the DSP are polishing and formulation.  The polishing step is done in 
order to remove traces amounts of contaminants.  Usually, the polishing step is done with either 
size exclusion or TFF [139].  After polishing, the product goes to final formulation.  The biggest 
challenge in the DSP is to keep pace with the increase in the upstream yields [139].  Virus 
flocculation with osmolytes for virus purification could be uses as a novel and economical 
alternative. 
2.6. Vaccine delivery systems  
Vaccine development requires that the vaccine is effective and can give a specific 
immune response [173].  Conventional vaccines, such as live-attenuated vaccines and whole 
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inactivated vaccines have been very successful at inducing immune responses against several 
virus infections.  However, these types of vaccines are reactogenic and often create unwanted 
side effects.  Moreover, conventional vaccines offer poor immune response in 
immunocompromised patients.  Additionally some pathogens are very difficult to grow in cell 
culture (e.g. HCV & HAV) [174].  To ameliorate these limitations, scientists have focused on new 
technologies, such as recombinant proteins subunit, synthetic peptides, protein-polysacharrides 
conjugates and plasmid DNA vaccines.  These types of vaccines are safer and less reactogenic 
than conventional vaccines, but they are also less immunogenic [174-177].  In order to induce an 
effective immune response in new technologies, vaccines require boosting agents, which are 
called adjuvants.  Adjuvants need to be capable of stimulating a protective immune response and 
be safe for humans [173, 178].  Adjuvants can be classified into immunostimulatory adjuvants 
and vaccine delivery systems [174].  Immunostimulatory adjuvants are derived from pathogens, 
and are known to stimulate immunity as they are identified by pattern recognition receptors, which 
are known to activate the cells of the immune system.  Vaccine delivery systems or vehicles are 
gaining attention in the medical field.  The vaccine antigen is either encapsulated or attached onto 
the surface of the vehicle [6, 174, 179].  The advantages of vaccine delivery systems include, 
specifically targeting the immune cells and incorporation of an adequate dose, so that booster 
doses are not necessary [179, 180].  Adjuvants are able to boost, maintain and potentiate an 
immune response against the antigen, and consequently they could lead to the improvements of 
vaccine products, vaccination coverage, and reduction of costs in the manufacturing processes 
[181].  Thus, they have the potential to be useful against viral diseases for which there are no 
effective vaccines yet.  The same systems used in drug delivery are used in vaccine delivery.  In 
2008, the demand for drug/vaccine delivery system was predict to increase by more than 10% a 
year [182] and is predict to reach $160 billions by 2016 [183]. 
A drug/vaccine delivery system can be classified based on the route of administration, 
either topical (skin or mucous), enteral (oral), or parenteral (injection) [182].  Oral and mucosal 
delivery vehicles could help to efficiently transport the virus antigen to the immune system and 
improve the therapeutic outcome of conventional vaccines that are administered by the parenteral 
47 
?
route, such as measles, and chickenpox (varicella) [184, 185].  Vaccines that are administered 
through this route present several limitations, such as risk of transmission of diseases, poor 
solubility, tissue damage, rapid breakdown of the therapeutic ???????, poor distribution and lack of 
target selectivity [184].  A controlled drug/vaccine delivery systems is designed to control the rate 
and period of a specific type of therapeutic in a specific target area of the body [186].  A 
drug/vaccine delivery system can also be classified by the delivery mechanism into active or 
passive [182].  An active mechanism permits the controlled initiation of release of a therapeutic by 
using a chemical feauture of the vehicle.  A passive mechanism allows the controlled release of 
the therapeutic by molecular diffusion, and the release mechanism usually takes advantage of 
human physiology [182].  The main goal of a vaccine/drug delivery system is to transport the 
therapeutic product to the patient by using the optimum route and the best mechanism [187].  
Vaccine delivery systems are in an early stage of development.  The discovery of efficient 
vaccine delivery vehicles may allow the development of more effective vaccines.   
Scientists have classified vaccine/drug delivery vehicles into virus-like particles (VLPs), 
liposomes, immune-stimulating complexes (ISCOMs), polymer-based nanoparticles, and non-
degradable nanoparticles [6, 173, 187].  VLPs are self assembly viral envelope without genetic 
material [188] (Figure 2.5A).  They are the great interest, because they can stimulate strong 
immune responses [189, 190].  Vaccines based on VLPs, such as the hepatitis B virus surface 
antigen (HBsAg) [191] and the human papilloma virus capsid protein L1 [192] are been used as 
commercial vaccines.  The baculovirus expression system is the most commonly used for the 
generation of VLPs.  The main disadvantage of VLPs production is the inability of this expression 
system to produce mammalian glycoproteins [6].  Liposomes are biodegradable molecules that 
can consist of a phospholipid bilayer shell with an aqueous interior [193] (Figure 2.5B).  They can 
improve the immunogenicity of weak proteins antigens by simulating the structure of natural lipid 
bilayer membranes and entering cells through endocytosis [193-195].  Some of these delivery 
systems are in the market or under clinical trials, and are used for the treatment of IFV-A & B and 
HAV infections [196].  The biggest limitations of liposomes are low stability, low encapsulation 
efficiency, rapid leakage of water-soluble drugs, poor storage stability, laborious manufaturing 
48 
?
process and poor quality assurance [177, 197, 198].  ISCOMs are open, cage-like complexes that 
are made with saponin, cholesterol, and phospholipids [6, 173, 199] (Figure 2.5C).  The antigen 
can be attached into the membrane of the ISCOMs or encanpsulated inside the ISCOMs [6, 177].  
ISCOMs are able to boost the imune system by promoting high levels of antibody and strong T-
cells responses [179].  ISCOMs incorporating recombinant hepatitis B surface antigen have 
shown immune response throught intranasal administration [200].  The two main problems with 
ISCOMs are stability and toxicity [177]. 
?
Figure 2.5.  Vaccine delivery systems.  A) Virus-like particle, B) Liposome, C) ISCOM, D) 
Polymeric nanoparticle, E) Non-degradable nanoparticle [6].1 
 
Polymer nanoparticles are the great interest since they are biodegradable molecules 
[201], which can be used to improve antigen stability and target delivery at slow release rates 
[183] (Figure 2.5D).  The have been used for nasal and oral delivery [179].  They can be divided 
into nanocapsules and nanospheres. In nanocapsules, the antigen is surronded by a polymer 
membrane, and in nanospheres, the drug is uniformly dispersed throughout the polymeric matrix 
??????????????????????????????????????????????????????
?
1 Reproduced from [6] Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. 
Frontiers in cellular and infection microbiology. 2013;3. with permission of Frontiers. ?
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[173, 181, 197].  The biggest disadvantage of polymer nanoparticles is the high cost involved in 
the production.  Non-degradables nanoparticles, are commonly made of gold, silica or carbon [6] 
(Figure 2.5E).  They have a shell where the vaccine antigen is encapsulated or attached [6].  
Gold nanoparticles are monodispers and uniforme in shape, which allow consisintency of 
mainting vaccine loading between batches [6].  Silica-based materials are prepared with 
surfactants, such as polymers and phospholipids using a hydrolysis and condensation technique 
(Figure 2.6).  The materials can be arranged into different morphologies, such as 
microsshpheres and monoliths [202].  They resulting particles possess a mesopores within the 
surface, which are used to pack and protect the vaccine antigen.   
?
Figure 2.6.  Silica-based material using unilamellar liposomes with a high sol–gel temperature 
transition phase as a template [202].2 
 
Mesoporous materials are potential vaccine delivery vehicles due to all the features they 
offer, such as an ordered pore network that allow load and release of the vaccine; high pore 
volume, which allow to hold the required amount of vaccine; and a high surface area that is 
required for vaccine delivery [186].  The first mesoporous silica-based material MCM-41, a highly 
ordered mesoporous material was synthetized in 1991.  Researchers were atracted to this 
material due to their potential to be used in technological applications, such as catalysis, lasers, 
sensors, and solar cells [187].  In 2001, the MCM-41 was proposed as a drug delivery vehicle and 
??????????????????????????????????????????????????????
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2 Reproduced from [202] Begu S, Durand R, Lerner DA, Charnay C, Tourne-Peteilh C, 
Devoisselle JM. Preparation and characterization of siliceous material using liposomes as 
template. Chem. Commun. 2003:640-1. with permission of The Royal Society of Chemistry. DOI: 
10.1039/B210927A 
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was used to transport ibuproben, an antiinflammatory drug [203].  After MCM-41, SBA-15 and 
MCM-48 have been shown to transport and release several types of drugs such catopril, 
erythromycin and gentamicin [186].  Althought silica-based mesoporous materials have been 
succesful employed for the delivery of several types of drugs, they have been reported to weaken 
the immune system [204, 205].  Researches have foccused on carbon-based mesoporus 
materials as an altertanive to silica-based materials. 
Mesoporous carbon is a new, synthetic, non-nano, and porous type of material that could 
be used as a smart delivery vehicle.  They are of great interest in many applications besides 
vaccines delivery, such as separation, catalysis and energy conversion and storage [206].  The 
advantages of this type of material include large pore accessibility and tunability of the pore 
structure.  The synthesis of this type of material can be made by hard template or soft template 
methods [206].  The conventional hard template method use silica as a template [207].  The 
method is complex, since the scaffolds need to be prepared, carbonization conditions are harsh, 
chemicals are corrosive, and finally the structures tend to collapse [208].  The soft-template 
method involves the self-assembly of surfactant micelles in the carbon precursor matrix (Figure 
2.7) [209].  In the soft-template method, the mesoporous carbon is synthetized by crosslinking an 
organic resin with surfactant, usually amphiphilic block copolymers.  The process is followed by 
pyrolysis, where the surfactants are removed and carbonization of the matrix [209].  The 
advantages of the soft-template method compared to hard-template include high microporosity, 
high surface area and a relatively large volume of mesopores [210].  Mesoporous carbon 
materials are projected to be potential candidates for biological applications such as drug delivery 
vehicles [186].  Mesoporous carbon materials are known to have a high surface area and an 
ordered pore system, which could assist with the adsorption and release process of multiple 
types of therapeutics, including vaccines 
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Figure 2.7.  Soft-template technique.  Self-assembly of mesoporous carbon by using a carbon 
precursor and a surfactant [209].3 
?
Soft-templated mesoporous materials possess an ordered pore network, which permit 
controlled drug/vaccine release, the high surface area and large pore volume allow the uptake 
and transport of a large amount of drug/vaccine [186].  Other advantages include low bulk 
density, which allows the material to float in the gastrointestinal system, when used in oral 
delivery, and the ability to adhere to the gastrointestinal system [182].  Recently studies have 
reported that soft-template mesoporous materials have successfully shown controlled release of 
model drugs, including antypirine, captopril, furosemide, and ranitidine hydrochloride [209, 211].  
In order to approve any type of biomaterial as a drug delivery vehicle, ???????? biocompability and 
toxicity tests are required prior to ??????? animal models and clinical trials [212, 213].  We propose 
that soft-templated mesoporous carbon materials have the potential to be used as drug delivery 
carriers, since they have shown low toxicity and high biocompatibility with model mammalian cells 
[214].  We would like to take advantage of these features and use these materials as potential 
vaccine/drug delivery vehicles (Chapter 6). 
 
 
??????????????????????????????????????????????????????
?
3Reprinted from Carbon, Vol 71, Saha D, Warren KE, Naskar AK, Soft-templated mesoporous 
carbons as potential materials for oral drug delivery, Pages 47-57, Copyright 2014, with 
permission from Elsevier.?
52 
?
2.7. Conclusions 
Natural antiviral compounds, improvements in current unit operation in the vaccine 
manufacturing process and the creation of effective vaccine delivery vehicles will help to reduce 
the mortality and the morbidity cause by viral diseases.  In this study, we propose to use natural 
products as new antiviral compounds because they are less expensive than synthetic drugs.  In 
the area of vaccine manufacturing, we propose virus flocculation in osmolytes, followed by 
microfiltration as an economical alternative.  Osmolytes have several advantages; they are able 
to preferentially flocculate hydrophobic virus, while leaving contaminants in solutions, and have 
been used as an excipient to stabilize therapeutics.  Therefore, they could be integrated into the 
process without adding new compounds that may require toxicity testing and additional removal 
processes.  Vaccine delivery vehicles are of great interest these days, since they can increase 
the immune response, without the use of large doses.  In this study we propose soft-templated 
mesoporous carbon materials as vaccine delivery vehicles.  The biggest advantage of this 
material is that they can control the released of the vaccine in the specific target area. 
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Chapter 3 
 
Osmolytes as antiviral compounds against porcine parvovirus1 
 
   
??????????????????????????????????????????????????????
?
1?The material contained in this chapter was previously published in Antiviral Research. Reprinted 
from Antiviral Research, vol. 99, Tafur, M. F., Vijayaragavan, S. V., Heldt, C. L. Reduction of 
porcine parvovirus infectivity in the presence of protecting osmolytes, Pages 27-33, Copyright 
2013, with permission from Elsevier.?
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3.1. Introduction 
Many diseases are caused by pathogenic virus infection.  In recent decades, scientists 
have defined the structure and function of many different viruses.  This has aided in the creation 
of specific antiviral compounds.  Compounds that inactivate certain viruses have changed the 
treatment of many diseases, including respiratory syncytial virus (RSV) [1] and herpes simplex 
virus type-1 (HSV-1) and type-2 (HSV-2) [2].  The AIDS epidemic has been treated with HIV 
protease inhibitors that now allow people to live decades with the virus [3].  However, there is still 
a need for the continued discovery of antiviral compounds.   
Many researchers are now studying natural products as a source of antiviral compounds, 
since viruses are starting to become resistant to current drugs [4].  In an effort to find natural 
compounds that have antiviral activity, we screened the antiviral activity of a panel of osmolytes 
and a salt against the non-enveloped virus porcine parvovirus (PPV).  Osmolytes are small 
organic compounds that are found in the cells of many organisms and they have the ability of 
stabilize intracellular proteins against environmental stress, such as extreme temperature or high 
osmotic pressure [5].  A balance between protecting and denaturing osmolytes assist in the 
delicate equilibrium needed for protein stabilization [6].  Protecting osmolytes fold proteins by 
structuring the water around themselves and changing the interaction between water and the 
protein backbone.  Denaturing osmolytes bind directly to the protein backbone, causing the 
protein to unfold [7].   
Parvoviruses, from the family ????????????, are small, non-enveloped, icosahedral, 
single-stranded DNA viruses that infect vertebrates and arthropods [8].  PPV infects the intestines 
of pigs and is the most frequent cause of swine reproductive failure [9].  This virus is often used 
as a model for the human parvovirus B19.  Although different natural compounds have been 
studied in recent decades, osmolytes have not been previously shown to have antiviral activity.  
This study describes the reduction of PPV infectivity in the presence of the protecting osmolytes 
TMAO and glycine.  
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3.2. Materials and methods 
3.2.1. Materials 
The osmolytes trimethylamine N-oxide (TMAO) dihydrate, glycine, betaine, D-alanine, D-
arginine, sucrose, trehalose dihydrate, urea, and the salt ammonium sulfate were purchased from 
Sigma-Aldrich (St. Louis, MO) at a minimum purity of ?98.0%.  Poly-L-lysine, 4?,6-diamidino-2-
phenylindole dihydrochloride (DAPI), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT), agarose type I, low EEO, neutral red solution (0.33%), and sodium dodecyl 
sulfate (SDS) were purchased from Sigma-Aldrich (St. Louis, MO).  Phosphate-buffered saline 
(PBS, pH 7.2) and 0.25% trypsin/EDTA for cell propagation were purchased from Life 
Technologies (Grand Island, NY).  12.1 M hydrochloric acid (HCl) and 3.7% formaldehyde in 
water were purchased from VWR (Radnor, PA).  The monoclonal mouse anti-PPV antibody was 
purchased from VMRD (Cat no. 3C9D11H11, Pullman, WA) and the polyclonal Alexa fluor 546-
conjugated rabbit anti-mouse antibody was purchased from Life Technologies (Cat no. A11060, 
Grand Island, NY).  All solutions were made with NanoPure water (Thermo Scientific, Waltham, 
MA, resistance >18 M?) and filtered with either a 0.2 ?m syringe filter (Nalgene, Rochester, NY) 
or a Millipore 0.2 ?m bottle top filter (Billerica, MA) prior to use. 
3.2.2. Cell propagation 
Porcine kidney (PK-13) cells were a gift from Dr. Ruben Carbonell at North Carolina State 
University and were propagated as described previously [10].  Briefly, the cells were grown in 
minimum essential medium (MEM) (Life Technologies, Grand Island, NY), supplemented with 
10% fetal bovine serum (FBS) (Atlanta Biologicals, Oakwood, GA) and 1% penicillin/streptomycin 
(Life Technologies, Grand Island, NY). 
3.2.3. Virus production and titration 
PPV strain NADL-2 was a gift from Dr. Ruben Carbonell at North Carolina State 
University and were propagated in PK-13 cells, as described previously [10].  Briefly, cells were 
infected with 103 MTT50 of PPV, and 1.5 h later 9 ml of supplemented media were added.  After 4-
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6 days, the flasks were placed at -20°C.  The flasks were thawed, and the monolayer was 
scraped.  The scraped cells and media were centrifuged at 5000 rpm in a Sorvall ST16R 
Centrifuge (Thermo Scientific, Pittsburgh, PA) at 4°C for 15 min to remove the cell debris.  The 
supernatant was stored at -80°C. 
PPV was titrated with a colorimetric cell viability assay, the MTT Assay [10].  The 
reduction of the MTT tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) inside the mitochondria of metabolically active cells produces formazan crystals [11].  
Upon dissolving the crystals, the cell viability can be quantified by measuring the absorbance of 
the solution at 550 nm.  This has been shown to be linearly comparable to a TCID50 for PPV on 
PK-13 cells [10].  Cells were seeded in 96-well plates, as described earlier [10].  The cells were 
infected with PPV in quadruplicate and 5-fold serial dilutions were made across the plate.  After 
five days, 10 ?l/well of 5 mg/ml of MTT in PBS was added.  Four hours later, 100 ?l/well of 
solubilizing agent (0.01M HCl and 10% SDS) were added.  Plates were read on a Synergy Mx 
microplate reader (BioTek, Winooski, VT) at 550 nm between 18-24 h after addition of the 
solubilizing agent.  The 50% infectious dose (MTT50) value was determined to be the virus dilution 
that yielded 50% of the uninfected cell absorbance.  The value was converted to a per milliliter 
basis and stated as the MTT50/ml titer [10]. 
3.2.4. Cytotoxicity assay 
Antiviral activity was determined in a similar way to the virus titration described in 
Section 3.2.3.  After virus was added to the cells, 25 ?l of osmolyte or salt at various 
concentrations were added to the infected cells.   
To determine the effect of osmolyte concentration on antiviral activity, 25 ?l of either 
TMAO or glycine with a final concentration ranging from 0.00 to 0.30 M was added to the infected 
cells.  To determine the effect of the time between infection and osmolyte addition on antiviral 
activity, 0.20 M of either TMAO or glycine was added at various times post-infection.  MTT 
reagent addition was performed after five days, as described in Section 3.2.3.  Calculation of the 
log reduction is shown in Eq 3.1. 
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3.2.5. Osmolyte toxicity 
Cell viability was assessed with an MTT assay and was used to determine the toxicity of 
TMAO and glycine to PK-13 cells.  Cells were seeded as described in Section 3.2.3 in 100 ?l of 
media.  Osmolytes diluted to a final concentration ranging from 0.00 to 0.60 M in NanoPure water 
were added to the cells after 24 h at a volume of 25 ?l.  MTT reagent addition was conducted 
after five days, as described Section 3.2.3.  Calculation of the % survival of cells is shown in Eq 
3.2. 
?????????? ? ???????????? ????????????????????????????????? ?      (3.2) 
3.2.6. Pre-infection treatment 
Pre-infection treatment was measured with an MTT assay.  PK-13 cells were seeded as 
described in the Section 3.2.3.  PPV virus was incubated with the osmolytes diluted to a final 
concentration ranging from 0.06 – 0.60 M in water for two hour before adding to the cells in five-
fold dilutions.  MTT reagent addition and the calculation of the virus titer were done as described 
in Section 3.2.3. 
3.2.7. Plaque reduction assay 
Plaque assays were performed as described previously [10].  Briefly, PK-13 cells were 
seeded into 25 cm2 tissue culture flasks with a final concentration of 4 × 105 cells per flask and 
incubated at 37°C and 5% CO2 until 70% confluent.  Ten-fold serial dilutions of 108 MTT50/ml 
were made in either PBS with 3% FBS or PBS with 3% FBS containing 0.20 M TMAO or 0.20 M 
glycine.  Cells were infected with 200 μl of different sample dilutions.  After 1 h of incubation, virus 
inoculum was removed and infected cells were overlaid with 1:1 of 2% agarose in Nanopure 
water and 2 x supplemented media.  Overlay media for osmolytes samples also contained 0.20 M 
glycine or 0.20 M TMAO.  Flasks were stained with 2 ml of 4% neutral red at 3.3 g/L in the 
overlay media after 4 days of incubation.  Plaques were counted 4-8 h after staining. 
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3.2.8. Yield reduction assay 
Intracellular and extracellular viable virus particles were measured.  PK-13 cells were 
seeded in 6-well plates at the same cell density as the MTT Assay described in Section 3.2.3.  
Cells were infected with 2 x 103 MTT50 of PPV.  After 1 h, the virus inoculum was removed and 
media added.  Osmolytes were added either at this time (Treatment 1) or 5 min prior to sample 
collection (Treatment 2).  Virus supernatant was removed at various times to measure 
extracellular viable virus particles.  To assay intracellular viable virus particles, cells were 
detached by the addition of trypsin/EDTA and equal volume of media was added to deactivate the 
trypsin.  All samples were frozen at -20°C for 24 h, thawed at room temperature, and centrifuged 
at 5000 rpm in a Sorvall ST16R Centrifuge (Thermo Scientific, Pittsburgh, PA) for 15 min at 4°C.  
The supernatants were removed and titrated as described in Section 3.2.3. 
3.2.9. Immunohistochemical detection of virus capsid protein production 
Intracellular virus capsid protein production was assessed through immunohistochemistry 
of PPV-infected cells with and without osmolytes. Glass slides (25 x 75mm) from VWR (Radnor, 
PA) were soaked in 2 M HCl for 1 h to etch and remove any grease.  Then, 200 ?l of poly-L-lysine 
was added on the area of cell growth.  After five minutes, the slides were washed with water and 
dried for 2 h under UV light.  Cells were seeded on the slides at a density of 5 x 104 cells/slide 
with a total volume of 50 ?l/slide.  Cells were incubated for 6 min at 37°C, and 5% CO2.  Ten ml of 
fresh media was added to the petri dish that contained the slides.  After 48 h of incubation, the 
media was removed and cells were washed with PBS.  Each slide was infected with 50 ?l/slide of 
either PPV (108 MTT50/ml), PPV containing 0.20 M TMAO or glycine (108 MTT50/ml), PBS, or 
media containing 0.20 M TMAO or glycine.  After 30 min, the cells were washed twice with PBS 
to remove any unattached PPV, and 10 ml of fresh media with or without osmolytes were added.  
The cells were placed at 37°C, 100% humidity, and 5% CO2 for different times.  The media was 
removed and the cells were washed once with PBS.  The infected cells were fixed with 200 ?l of 
3.7% formaldehyde for 20 minutes at room temperature, and then washed twice with PBS.  The 
cells were blocked with 200 ?l of 0.3% low-fat milk in PBS.  After 1 h, 50 μl of 1:100 v/v anti-PPV 
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antibody were added and incubated for 1 h at 37°C followed by two PBS washes.  Then, 50 μl of 
Alexa fluor 546-conjugated rabbit anti-mouse IgG (1:500 v/v) were added and incubated for 1 h at 
37°C followed by two PBS washes.  Slides were washed again with PBS.  To fix the antibodies, 
200 ?l of 3.7% formaldehyde were added for 20 min at room temperature, and then the cells were 
washed twice with PBS.  Finally, 50 μl of 150 μM DAPI were added for 5 minutes at room 
temperature and washed with PBS.  Images of the cells were taken with an Olympus IX51 
microscope with a DP72 camera (Olympus, Center Valley, PA).  Fluorescence per cell was 
analyzed with ImageJ (NIH).  Image study was conducted on 2-3 slides with 10 images per slide. 
All images were procured from Olympus CellSens imaging software.  The ImageJ 
analysis was performed by gray scaling 100 ms exposure PPV images and 5 ms exposure DAPI 
images.  The obtained multi-color images were converted to single color images by converting to 
16 bit or a gray scale image (Figure. 3.1).  The threshold was adjusted and consistent values 
were maintained to analyze the entire set of images.  A binary version of the image was created 
with pixel intensity of 0 (white) and 255 (black).  Any noise levels less or equal to 2 pixel density 
was removed and each image was analyzed for particle count and area.  The PPV/DAPI ratio 
was determined by taking the area of the binary PPV image and dividing by the number of nuclei 
found in the DAPI binary image (see Figure 3.1). 
3.3. Results  
3.3.1. Virus cytotoxicity in the presence of osmolytes and a salt 
Antiviral activity of a group of osmolytes and a salt was screened.  These compounds 
were the protecting osmolytes TMAO, betaine, sucrose, glycine, alanine and trehalose, the 
denaturing osmolyte urea, and the salt ammonium sulfate.  Two to three different concentrations 
of each osmolyte and salt were tested for their ability to reduce the infectivity of PPV (Figure 3.2).  
Cell viability was measured with the MTT assay.  Reduction of cell viability can be caused by 
either the compound toxicity or the virus cytotoxicity.  The MTT assay has been compared to a 
TCID50 (i.e. visual inspection of cell death) for PPV cytotoxicity on PK-13 cells, and shown to be 
linearly correlated [10].  
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Figure 3.1.  Binary images produced in ImageJ for immunohistochemistry analysis. 
?
?
Figure 3.2.  Antiviral activity of a panel of osmolytes and a salt. 7 log10(MTT50/ml) of PPV was 
used to infect cells in media with different osmolyte concentrations for five days.  This was 
followed by the evaluation of virus cytotoxicity with the MTT assay.  The stars represent the 
osmolytes with the greatest antiviral activity.  The maximum detection limit of the assay was 9.6 
log10(MTT50/ml).  All data points are the average of three separate experiments and the error bars 
represent the standard deviation. 
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A value of 9.6 log10(MTT50/ml) indicates that none of the cells were viable.  At all 
osmolyte concentrations tested, sucrose, alanine and ammonium sulfate were found to be toxic to 
the cells, and therefore no viable cells were detected (Figure 3.2).  All other compounds tested, 
except for trehalose, demonstated compound toxicity at the highest concentrations tested.  
TMAO, betaine, urea, and glycine were all toxic at 0.60 M.  They demonstrated antiviral activitiy 
at 0.20 M and then returned to near PPV control values at 0.06 M.  For most compounds, this 
return to PPV control values is due to the compound being present at too low of a concentration 
to have antiviral activity.  In the case of betaine and trehalose, the lowest concentration of 
osmolyte increased the virus titer above the control.  It is possible that at low concentrations, the 
compounds increased and enhanced the virus’ ability to infect the cells.  This has been seen for 
other compounds [12]. 
TMAO and glycine at a concentration of 0.20 M showed a four log reduction, which is 
equal to 99.99% of infectious virus reduction.  These two osmolytes had the greatest antiviral 
activity and were the focus of all subsequent work. 
3.3.2. Osmolyte toxicity 
Osmolyte toxicity was measured in PK-13 cells.  As Figure 3.3A shows, the cells had a 
high rate of survival at low doses of osmolytes.  Increasing the osmolyte concentration resulted in 
a decrease in cell survival, likely due to hypotonic lysis of the cells.  TMAO exhibited a sigmoidal 
dose response with a calculated 50% inhibitory concentration (IC50) of 0.37 ± 0.01 M.  Glycine did 
not display a clear sigmoidal curve, but an IC50 value of 0.42 ± 0.02 M was calculated 
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Figure 3.3.  Osmolyte toxicity and reduction of virus cytotoxicity with different concentrations of 
TMAO and glycine.  (A) Osmolyte toxicity on PK-13 cells, a susceptible host for PPV in the 
presence of glycine and TMAO, and (B) log reduction of PPV infectivity in the presence of various 
concentrations of glycine and TMAO.  Cells and infected cells were exposed to osmolytes for five 
days, followed by evaluation of cytotoxicity with the MTT assay.  The log reduction is defined in 
Eq. 3.1. and the % survival is defined in Eq. 3.2.  All data points are the average of three separate 
experiments and the error bars represent the standard deviation. 
 
3.3.3. Reduction of virus cytotoxicity with TMAO and glycine 
The antiviral activities of various concentrations of TMAO and glycine were studied.  
Glycine and TMAO showed the highest log reduction, four logs (99.99%), at 0.20 M (22.29 
mg/mL of glycine and 15.01 mg/mL of TMAO) (Figure 3.3B).  The MTT Assay measures cell 
viability and this can be caused by compound toxicity or virus infectivity.  At high or low osmolyte 
concentration, cell viability was reduced probably due to compound toxicity or virus infectivity. 
Many antiviral compounds work by interrupting virus entry. However, some antiviral 
compounds work by interrupting replication.  To determine if disruption of virus entry was the 
antiviral mechanism of the osmolytes, the time between virus infection and osmolyte addition 
was varied.  When 0.20 M of TMAO or glycine was added at the initial stages of virus infection, a 
four log reduction in PPV infectivity was observed for both osmolytes (Figure 3.4).  As the time 
between virus infection and osmolyte addition increased, the reduction in infectivity slowly 
decreased over time and approached one log reduction (90%) at 20 h (Figure 3.4).   
81 
?
?
Figure 3.4.  Reduction of virus cytotoxicity in the presence of osmolytes added post-virus 
infection.  0.20 M glycine and 0.20 M TMAO were added at different times post-virus infection and 
after five days, followed by evaluation of virus cytotoxicity with the MTT assay.  The log reduction 
is defined in Eq. 3.1.  All data points are the average of three separate experiments and the error 
bars represent the standard deviation. 
 
Osmolytes are not likely disrupting virus entry because they were still effective when 
added 20 h post-virus infection.  Treatment of the virus with osmolytes prior to infection did not 
reduce virus infectivity, shown in Figure 3.5.  This demonstrates that the osmolytes are likely not 
disrupting virus attachment or entry. 
?
Figure 3.5.  Pre-infection treatment of PPV with osmolytes.  The virus and osmolytes were 
incubated for two hours prior to cell infection.  The virus was incubated with cells for five days 
prior to evaluation with the MTT Assay. 
 
3.3.4. Plaque reduction assay 
A plaque reduction assay was performed to corroborate data from the cytotoxicity assay.  
A plaque assay was performed for 0.20 M TMAO and 0.20 M glycine and a >7 log reduction was 
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found.  No plaques were formed in the presence of 0.20 M TMAO and glycine (Table 3.1). 
Table 3.1.  PPV plaque assay 
Sample Titer (pfu/ml) 
PPV 5.5 x 107 ± 1.1 x 107
0.2 M glycine + PPV ND* 
0.2 M TMAO + PPV ND* 
*not detected 
 
3.3.5. Impact of osmolytes on infectious virus yield 
The presence of intracellular and extracellular viable virus particles was examined.  This 
was studied under two different osmolyte treatments.  In Treatment 1, the osmolytes were added 
at the beginning of the infection cycle and in Treatment 2, they were added five minutes before 
sample collection.  Treatment 2 was done in order to determine if the addition of osmolyte after 
infection would affect the MTT assay.  As shown in Figure 3.6, there was no difference between 
Treatment 2 and the control (i.e. virus infection with no osmolytes addition).  
With Treatment 1, there appeared to be little infectious virus extracellularly (Figure 3.6A) 
or intracellularly (Figure 3.6B), even after 32 h.  Without osmolyte addition, infectious virus began 
to appear extracellularly after 15 h and intracellularly after 10 h. This is consistent with detection 
of an increase in DNA at about 8 h post infection [9].  After 32 h, 0.2 M TMAO and glycine had a 
3.5 ± 0.5 log and 4.2 ± 0.5 log reduction extracellularly, respectively, as compared to the PPV 
control, and a 2.9 ± 0.2 log and a 3.0 ± 0.5 log reduction intracellularly, respectively.  This is 
consistent with a >4 log reduction after five days incubation, as shown in Figure 3.4. 
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Figure 3.6.  Impact of osmolytes on infectious virus yield.  (A) Extracellular, and (B) intracellular 
infectious virus yield.  Osmolytes were added at the time of infection (Treatment 1) or 5 min 
before sample collection (Treatment 2).  The yield of infectious virus particles was determined 
with the MTT Assay.  The minimum limit of detection of the assay was 1.6 log10(MTT50/ml).  All 
data points are the average of three separate tests and the error bars represent the standard 
deviation.  Student’s t-test was used to evaluate the statistical significance between PPV infected 
cells containing osmolytes for Treatment 1 and PPV infected cells without osmolytes.  *p value of 
<0.05. 
 
3.3.6. Virus capsid protein production with the addition of osmolytes 
It was explored with immunohistochemistry if the virus capsid proteins were being 
produced within the cells.  PPV capsid proteins were found in all samples infected with PPV, 
including those containing 0.20 M TMAO and 0.20 M glycine (Figure 3.7A).  PBS without virus 
was used as a negative control, and did not show any virus capsid protein formation.  TMAO and 
glycine were also tested without virus present and no virus capsid protein formation was detected 
(data not shown).  In Figure 3.7B, fluorescence per cell started to increase after 8 h, and this 
agrees with virus production data (Figure 3.6B) and DNA production data [9], although we did not 
specifically test if PPV DNA was produced.  Similar trends were observed with PPV and 
osmolytes (Figure 3.7B).  These results show that viral capsid proteins are produced (Figure 
3.7B), but viable virus particles are not produced (Figure 3.6). 
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Figure 3.7.  Impact of osmolytes on virus capsid protein formation.  (A) Images of PPV and PBS 
mock infected cells at 16 h, and (B) the ratio of the fluorescence of PPV capsid proteins to the 
count of DAPI.  All data points are the average of three independent slides with 10 images per 
slide and the error bars represent the standard deviation.  TMAO and glycine were tested in order 
to determine osmolytes cross-reactivity with antibodies and no virus capsids were found (data not 
shown).  Student’s t-test was used to evaluate the statistical significance between cells infected 
with PPV (with or without osmolyte) and the PBS negative control. *p value of <0.05 
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3.4. Discussion 
Antiviral compounds are known to disrupt virus entry, replication, assembly of virus 
particles, or a combination of these.  Antiviral compounds that destroy the enveloped capsid of a 
virus are required in small quantities [13].  Other compounds are able to alter the virus-host 
interactions and are required in higher quantities [14].  The advantage of natural compounds that 
alter the virus-host interactions is that they can be applied post-infection.  In this study, two 
osmolytes, TMAO and glycine, demonstrated this behavior and are therefore promising 
candidates for therapeutic drugs.  TMAO and glycine are both small (molecular weight of 75 
g/mol), zwitterionic species.  More work will need to be done to determine why these osmolytes, 
compared to the many that were tested (Figure 3.2) demonstrated antiviral activity.  
The fact that virus capsid proteins were produced in the presence of osmolytes (Figure 
3.7) strongly suggests that osmolytes work post-virus infection (Figure 3.4 & 3.6).  We 
hypothesize that osmolytes are disrupting capsid assembly by stabilizing viral capsid proteins and 
preventing the assembly process.  Osmolytes stabilize proteins by causing a preferential 
hydration around proteins [5].  TMAO has also been shown to preferentially order water 
molecules around ?-chymotrypsin and to stabilize the enzymatic activity of the protein [15].  This 
preferential hydration causes proteins to adapt a compact configuration [16].  It is likely that this 
compact configuration of the VP2 protein in PPV is not able to self-assemble into a virus capsid.  
The protein capsids of other parvoviruses have been studied and their assembly is likely to be 
kinetically stable, but not thermodynamically stable [17].  This may demonstrate that the 
osmolytes thermodynamically stabilize the capsid proteins, therefore reducing their propensity to 
kinetically assemble.  The other possibility is that the high osmolyte concentration in the cells 
reduces the activity of the assembly machinery that guides the DNA inside the virus capsid.  
However, enzymes are usually stabilized and still have activity in a solution of osmolytes [15], 
therefore, we hypothesize that the osmolytes are disrupting the ability of the capsid proteins to 
self-assemble. 
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3.5. Conclusions 
A variety of osmolytes were screened to find antiviral compounds against PPV, a small, 
non-enveloped, single-stranded DNA virus [18].  We have discovered that two protecting 
osmolytes, TMAO and glycine, at 0.20 M, reduce the infectivity of PPV by four logs (99.99%).  
These results are consistent with the literature, since high quantities of antiviral compounds are 
often required for the inactivation of non-enveloped viruses.  Both osmolytes showed antiviral 
activity after being added 20 h post-infection.  In the presence of TMAO or glycine, infected cells 
produce virus capsid proteins, but not infectious viable virus particles.  We propose that the 
osmolytes TMAO and glycine interfere with the virus capsid formation and are potential 
candidates for therapeutic drugs. 
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Chapter 4  
Purification of porcine parvovirus with osmolytes flocculation, 
followed by microfiltration1    
??????????????????????????????????????????????????????
?
1?The material contained in this chapter was previously published in Journal of Biotechnology. 
Reprinted from Journal of Biotechnology, Vol. 186, Gencoglu, M. F., Pearson, E., Heldt, C. L. 
Porcine parvovirus flocculation and removal in the presence of osmolytes, Pages 83-90, 
Copyright 2014, with permission from Elsevier.?
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4.1. Introduction 
More than 90% of all human diseases are caused by viral infections [19].  However, 
viruses do not only cause disease; they can be modified into viral vaccines or viral vectors to 
prevent or treat diseases [20].  Many viral diseases, like yellow fever and polio, are under control 
due to the development of effective vaccines [21].  Treatment of a wide variety of diseases, such 
as cancer and Alzheimer’s disease, will benefit from future viral gene therapy vectors [22-24].  
The World Health Organization (WHO) reported in 2010 that the vaccine market growth rate is 
10-15% per year, higher than the growth rate of other pharmaceuticals at 5-7% per year [25].  
Since there is a large market for viral vaccines, a more efficient method to manufacture and purify 
viral particles is needed.  Lyddiatt and Sullivan estimated that between 1011 and 1014 viral vectors 
will be required for a single dose of gene therapy vectors [26].  Due this large dosage, an 
efficient, cost-effective, and quick process will be required to satisfy the viral vector market 
demand. 
Conventional virus purification techniques, like ultracentrifugation and density gradient 
centrifugation, have been used to isolate viruses at the laboratory scale [27, 28].  However, due 
to the size of the equipment, the difficult scale-up, long processing times, and low purity, 
ultracentrifugation remains cost-ineffective for large-scale vaccine production [29-31]. 
Alternatives such as filtration and chromatography have been used to overcome the 
disadvantages of ultracentrifugation.  Tangential flow filtration (TFF) has effectively recovered and 
purified virus particles [32, 33].  TFF is successful due to the large size difference of virus 
particles and typical protein contaminants.  The main advantages of TFF are easy scalability, high 
throughput, high viral titer and high viral recoveries [34-36].  However, the capacity of the 
membranes can be affected by fouling and this can lead to longer filtration times, low flux through 
the membrane and high transmembrane pressures [37, 38].  Additionally, a platform approach for 
virus filtration does not exist, since the success of current processes depend on the properties of 
individual viral therapeutics [39].  
Chromatography is the predominant technique for large-scale virus purification [27, 40].  
91 
?
All of the typical chromatography modes have been utilized for virus particle purification [41].  The 
more successful chromatographic purification processes for viruses are combined with size-
based separation methods [27, 38].  However, a universal chromatography process cannot be 
applied to all the viruses, since the operating conditions depend on the charge, size, and 
specificity of the target virus [35, 42].  Moreover, conventional chromatography resins are 
designed for the purification of proteins, but not for large biomolecules, such as virus particles.  
Virus particles have difficulties accessing the high internal surface area of the resins [43, 44], 
making the resins highly inefficient.  Membrane chromatography has shown promise to overcome 
many of the disadvantages of pore accessibility in resin chromatography [45, 46].  However, there 
still remains the difficulty of optimizing the binding and elution conditions for each viral product 
without causing virus inactivation. 
Precipitation and flocculation followed by separation using centrifugation or filtration have 
been used as an alternative for virus purification [38].  Commonly, the additives are compounds 
that promote aggregation, like salts or polymeric agents [30].  Salts and polymers often 
precipitate all proteins in solution, although there have been reports of selective precipitation with 
these agents.  Ammonium sulfate at specific conditions has been shown to selectively precipitate 
immunoglobulin G (IgG) over bovine serum albumin (BSA) [47] likely due to the hydrophobicity 
difference of the two proteins [48].  Salts have been used to precipitate viruses from protein-free 
solutions [49-51].  Polyethylene glycol (PEG) is well-known to precipitate all proteins [52], 
although specific conditions have been found to selectively precipitate IgG4 from cell culture [53] 
and viruses from DNA and protein contaminants [54] using PEG.  However, PEG precipitation 
requires extended periods of incubation time [55] and polymer additives may interact with virus 
particles and form complexes that are difficult to dissociate [56, 57]. 
The aim in virus flocculation is to improve process robustness; a selective, global, 
nontoxic, and economical flocculant is desired [41].  In this study we propose to use osmolytes to 
overcome these challenges.  Osmolytes are found in the cells of many organisms, and their main 
goal is to stabilize intracellular proteins against environmental stresses, such as extreme 
temperatures or high osmotic pressures, by changing the water content of the cells [58-60].  
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There are two types of osmolytes, protecting and denaturing.  Protecting osmolytes have the 
ability to fold proteins by binding to the water molecules and changing the water contents around 
the protein backbone.  Denaturing osmolytes have the ability to unfold the proteins, by binding 
directly to the protein backbone [61].  One advantage of osmolytes, such as glycine, alanine and 
mannitol as compared to salt or polymer flocculants, is that they are often used as an excipient to 
stabilize the final formulation of biotherapeutics [62, 63], making them an ideal addition to a 
biotherapeutic manufacturing process. 
Porcine parvovirus (PPV), a non-enveloped, single-strand DNA, icosahedral virus, with a 
diameter of 18 - 26 nm [8, 19] was used to demonstrate the ability of osmolytes to preferentially 
flocculate virus particles.  We propose that osmolytes bind to water, thus leading to the reduction 
of a hydration shell around the virus and causing PPV particle aggregation.  Using high-
throughput screening methods, we have discovered that osmolytes flocculate PPV and 
demonstrate a >80% removal with a 0.2 ?m filter with <5% removal of model host cell proteins.  
This micropore filter is usually used to retain bacteria, and therefore this is a unique application of 
microfiltration for small virus particle removal and future purification. 
4.2. Materials and methods 
4.2.1. Materials?
The osmolytes, trimethylamine N-oxide (TMAO) dihydrate, glycine, betaine, D-alanine, D-
arginine, L-proline, L-serine, D-mannitol, sucrose, D-(+)-trehalose dihydrate, D-(+)-raffinose 
pentahydrate, and urea, and the salts, ammonium sulfate, sodium chloride (NaCl), magnesium 
sulfate, and magnesium chloride were purchased from Sigma-Aldrich (St. Louis, MO) at a 
minimum purity of 98%.  Sodium hydroxide (NaOH) and PEG, with a molecular weight (MW) of 
12,000 Da, and albumin from bovine serum (BSA) were also purchased from Sigma-Aldrich (St. 
Louis, MO).  Tris (hydroxymethyl) aminomethane hydrochloride (Tris) was purchased from 
Thermo Scientific (Waltham, MA).  MTT Assay reagents, thiazolyl blue tetrazolium bromide 
(MTT), sodium dodecyl sulfate (SDS) and hydrochloric acid (HCl) were purchased from VWR 
(Radnor, PA).  Cell culture reagents, phosphate-buffered saline (PBS, pH 7.2), 0.25% 
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trypsin/EDTA, 1% penicillin/streptomycin (pen/strep), and minimum essential medium (MEM) 
were purchased from Life Technologies (Carlsbad, CA).  Lysozyme, chicken egg white was 
purchased from EMD Millipore (Billerica, MA).  All the solutions were prepared with NanoPure 
water (Thermo Scientific, Waltham, MA) to a resistance >18 M?, or PBS and filtered with either a 
0.2 ?m syringe filter (Nalgene, Rochester, NY) or a Millipore 0.2 ?m bottle top filter (Billerica, MA) 
prior to use. 
4.2.2. Cell propagation, virus production and titration 
Porcine kidney (PK-13) cells were a gift from Dr. Ruben Carbonell at North Carolina State 
University.  PK-13 cells were grown at 37°C, 5% CO2 and 100% humidity in MEM supplemented 
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) and 1% pen/strep, as 
described earlier [10].?
PPV strain NADL-2 was a gift from Dr. Ruben Carbonell at North Carolina State 
University and was propagated as described previously [10].  Briefly, PK-13 cells were seeded 24 
h prior to inoculation with 1 ml of PPV at 103 MTT/ml diluted in PBS, 3% FBS and 1x pen/strep.  
After 1.5 h, 9 ml of fresh media was added and the infected cells were incubated for 5 days.  
Flasks were frozen, scraped, and clarified.  The clarified virus solution was stored at -80°C. 
PPV was titrated with a colorimetric cell viability assay, MTT assay, which has been 
described previously [64].  The MTT assay measures enzymatic activity in active mitochondria 
and can be used to quantify cytopathic effect of PPV in PK-13 cells.  Briefly, PK-13 cells were 
seeded in 96-well plates.  After 24 h, each plate was infected with PPV in quadruplicate and 5-
fold serial dilutions.  After ?ve days, the MTT solution was added, followed by solubilizing agent 4 
h later.  After 18 - 24 h, plates were read on a Synergy Mx microplate reader (BioTek, Winooski, 
VT) at 550 nm.  The 50% infectious dose (MTT50) value was defined as the virus dilution that 
achieved 50% of the uninfected cell absorbance.  The value was determined on a per milliliter 
basis and stated as the MTT50/ml titer [10]. 
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4.2.3. Virus flocculation and filtration 
To flocculate PPV, the clarified virus was diluted 1:100 in PBS to a final concentration of 
106MTT/ml, then 30 ?l was mixed with720 ?l of osmolytes solutions in NanoPure water for 2 h at 
room temperature, in triplicate.  As a control, NanoPure water was incubated with PPV.  Typically, 
the pH was not controlled.  However, it was checked to make sure that the pH remained 
consistent for each osmolyte over multiple trials.  For the pH studies, the pH was adjusted by 
addition of HCl or NaOH.  Flocculated virus particles were filtered in a high throughput manner 
with either a 0.2 ?m 96-well filter plate (Millipore, Billerica, MA) or a 300 kDa filterplate (Seahorse 
Bio, North Billerica, MA) at 200 × ? and 4°C for 20 min (40 min for the 300 kDa plate) in a Sorvall 
ST16R Centrifuge (Thermo Scientific, Pittsburgh, PA). Virus samples before and after filtration 
were titrated as described in Section 4.2.2.  Log reduction value (LRV) and % removal were 
calculated with Eq. 4.1 and 4.2, respectively, 
??? ? ???? ??????         (4.1) 
????????? ? ?? ? ???
??
???? ?? ? ???       (4.2) 
where ???is the concentration of infectious virus after filtration and ?? is the concentration of 
infectious virus before filtration. 
4.2.4. Shear stress effect  
Shear stress was generated on PPV aggregates at different glycine concentrations.  Low 
shear effect was generated with manual rotation for 2 h, medium and high shear effect were 
produced with a vortex, at low and high speed, respectively, for 2 h.  High-low shear effect was 
generated with 2 h at the vortex followed by manual rotation for 2 h.  Virus samples were 
flocculated and filtered as described in Section 4.2.3.  Samples before and after filtration were 
titrated as described in Section 4.2.2 and % removal was calculated with Eq. 4.2. 
4.2.5. Ionic strength effect  
The ionic strength effect on PPV flocculation was tested with the addition of NaCl to 
alanine and mannitol solutions.  The ionic strength (I) was calculated with Eq. 4.3, 
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where ???is the concentration of ion ?, ?? is the charge of ion ?.  Alanine is a zwitterionic molecule, 
while mannitol is a neutral molecule.  For alanine, two different values of ionic strength were 
calculated.  In both cases the experiment was the same, 1.0 M alanine had the same 
concentrations of NaCl, ranging from 0.2 M to 0.6 M, added to it.  However, different calculations 
of ionic strength were applied.  In one case, we assumed that alanine did not contribute to the 
ionic strength and in the other case, we assumed that alanine did contribute.  Mannitol was 
considered to not contribute to ionic strength.  For mannitol two sets of experiments were carried 
out, 0.2-0.6 M NaCl and 1.2-1.6 M NaCl was added to the 1 M mannitol solution.  The lower NaCl 
concentrations in mannitol were compared to alanine assuming it did not contribute to ionic 
strength and the higher NaCl concentrations in mannitol were compared to alanine assuming it 
did contribute.  Virus samples were flocculated and filtered as described in Section 4.2.3.  
Samples before and after filtration were titrated as described in Section 4.2.2 and % removal was 
calculated with Eq. 4.2. 
4.2.6. Protein flocculation and filtration 
BSA and lysozyme were diluted in PBS to a final concentration of 20 mg/ml.  30 ?l of 
protein solutions were mixed with 720 ?l of 1 M of mannitol or 1 M of alanine. After 2 h of 
incubation at room temperature, flocculated proteins were filtered as described in Section 
4.2.3.  Protein absorbance before and after filtration was measured on a Synergy Mx 
microplate reader at 280 nm.  % Protein removal was calculated with Eq. 4.4, 
???????????????? ? ???????? ? ? ???       (4.4) 
where ?? is the concentration of protein solution after filtration, and ?? is the concentration of 
protein solution before filtration. 
4.3. Results and discussion 
4.3.1. PPV flocculation in the presence of osmolytes, salts, and PEG 
A variety of osmolytes were screened for their ability to flocculate PPV (Figure 4.1).  In 
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addition, salts and PEG were used as positive controls and Tris buffer, PBS, and water were 
used as negative controls, since they have not been shown to flocculate proteins or virus 
particles.  Osmolytes were chosen because amino acids, a type of osmolyte, have been shown to 
flocculate the parvovirus B19 [65].  Salts were considered a positive control because salts have 
been used to flocculate virus particles such as enteroviruses and retroviral vectors [66, 67].  PEG 
has been used as a flocculent to recover virus particles [10, 68] and was also considered a 
positive control. 
?
Figure 4.1.  High-throughput screening of virus flocculants.  A variety of osmolytes were 
compared to the positive control salts and PEG and the negative controls, Tris, PBS, and water 
for flocculation of PPV using a 0.2 ?m micropore filter.  80% removal was used as the cut-off to 
pursue testing.  % removal is defined in Eq. 4.2.  All data points are the average of three separate 
experiments and the error bars represent the standard deviation. 
 
The protecting osmolytes glycine, alanine, sucrose, trehalose and mannitol flocculated 
PPV, and demonstrated a >80% removal with a 0.2 ?m filter (Figure 4.1).  This large micropore 
filter is usually used for bacterial removal, and not for small viruses [69], such as PPV with a 
diameter of 18 - 26 nm [19].  Salts such as magnesium sulfate and magnesium chloride 
presented a high virus removal (>80%) (Figure 4.1) as compared to ammonium sulfate and 
sodium chloride.  This is likely due to the fact that Mg2+ is a strongly hydrated cation, which 
decreases the protein and virus solubility and promotes aggregation.  Whereas, the NH4+ and Na+ 
ions are weakly hydrated cations, which are known to increase protein solubility and destabilize 
aggregates.  In PEG samples, virus removal was low compared to other positive controls and 
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many osmolytes (Figure 4.1), likely because PEG precipitation requires longer incubation times 
and lower temperatures than those tested here [55]. 
We confirmed that the reduction in virus titer was due to virus filtration and not virus 
inactivation in the osmolyte and control solutions tested (Table 4.1).   
Table 4.1.  LRV compared to water control 
Flocculant log10(MTT50/ml) LRVa 
3.0 M GLY 4.72 +/- 0.43 0.00 
1.0 M GLY 4.96 +/- 0.16 0.00 
0.3 M GLY 5.49 +/- 0.17 0.00 
1.0 M ALA 5.00 +/- 0.61 0.00 
0.3 M ALA 5.73 +/- 0.17 0.00 
1.0 M ARG 5.13 +/- 0.44 0.00 
0.3 M ARG 5.56 +/- 0.87 0.00 
3.0 M BET 4.75 +/- 0.30 0.00 
1.0 M BET 4.67 +/- 0.30 0.00 
0.3 M BET 4.48 +/- 0.15 0.17 
3.0 M PRO 4.65 +/- 0.58 0.00 
1.0 M PRO 4.77 +/- 0.04 0.00 
0.3 M PRO 5.00 +/- 0.45 0.00 
3.0 M SER 4.41 +/- 0.06 0.23 
1.0 M SER 4.52 +/- 0.22 0.12 
0.3 M SER 4.55 +/- 0.03 0.09 
3.0 M TMAO 5.34 +/- 0.11 0.00 
1.0 M TMAO 5.21 +/- 0.33 0.00 
0.3 M TMAO 5.11 +/- 0.46 0.00 
3.0 M UREA 4.46 +/- 0.73 0.19 
1.0 M UREA 4.08 +/- 0.12 0.57 
0.3 M UREA 3.35 +/- 0.45 1.30b
1.0 M SUC 4.47 +/- 0.13 0.18 
0.3 M SUC 4.67 +/- 0.13 0.00 
1.0 M TRE 4.60 +/- 0.27 0.05 
0.3 M TRE 4.62 +/- 0.34 0.02 
0.3 M RAF 4.77 +/- 0.18 0.00 
1.0 M MAN 4.62 +/- 0.39 0.02 
0.3 M MAN 5.38 +/- 0.47 0.00 
3.0 M S. CHL 4.69 +/- 0.35 0.00 
1.0 M S. CHL 4.52 +/- 0.16 0.12 
0.3 M S. CHL 4.46 +/- 0.21 0.18 
3.0 M A. SUL 3.42 +/- 0.04 1.22b
1.0 M A. SUL 3.10 +/- 0.10 1.55b
0.3 M A. SUL 2.46 +/- 0.04 2.18b
3.0 M M. SUL 3.92 +/- 0.10 0.72 
1.0 M M. SUL 5.13 +/- 0.31 0.00 
0.3 M M. SUL 4.46 +/- 0.56 0.19 
3.0 M M. CHL 4.51 +/- 0.76 0.14 
1.0 M M. CHL 4.94 +/- 0.34 0.00 
0.3 M M. CHL 4.65 +/- 0.20 0.00 
20% PEG 4.20 +/- 0.45 0.45 
10% PEG 4.56 +/- 0.38 0.08 
5% PEG 4.78 +/- 0.24 0.00 
TRIS 4.58 +/- 0.28 0.07 
PBS 4.11 +/- 0.59 0.53 
H2O 4.65 +/- 0.24 0.00 
aLRV was calculated with Eq. 4.1, where ???is the concentration of infectious virus in the presence of the flocculant and ?? 
is the concentration of infectious virus in the presence of water. bFlocculants that reduced the virus titer by > 1 LRV 
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This was done by testing the virus titer of each flocculating solution prior to filtration and 
comparing to the virus titer of the water control solution.  All tested concentrations of ammonium 
sulfate and 0.3 M urea reduced the virus titer by > 1 LRV, inactivating the virus prior to filtration 
(see Table 4.1).  None of the other osmolytes or salts tested inactivated the virus.  With evidence 
that virus flocculation with osmolytes, followed by microfiltration could be a potentially new virus 
purification process we pursued the evaluation of osmolytes to a greater extent. 
The osmolytes that were able to remove PPV with a 0.2 ?m filter were also tested with a 
nanopore filter, 300 kDa MWCO, which has an approximately 0.03 μm pore size.  The LRV was 
higher at 1.0 M for the all the osmolytes tested, except for glycine and sucrose with both filters 
(Figure 4.2A & B). 
?
Figure 4.2.  Effect of pore size and osmolyte concentration on log reduction value (LRV).  
Osmolyte concentrations of (A) 1.0 M and (B) 0.3 M.  LRV is defined in Eq. 4.1.  All data points 
are the average of three separate experiments and the error bars represent the standard 
deviation.  ?? value of <0.05 as compared to the water control using Student’s t-test. 
 
These results indicate that the concentration of osmolytes required to achieve high 
percent of virus removal may differ from osmolyte to osmolyte.  Alanine and mannitol filtered with 
a 300 kDa filter at a concentration of 1.0 M showed a 2.6 LRV (99.75% removal) and 3.5 LRV 
(99.97% removal), respectively (Figure 4.2A).  A 3.5 LRV is close to the 4 LRV minimum 
requirement by the Food and Drug Administration (FDA) [70] and the Environmental Protection 
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Agency (EPA) [71] for any virus removal step process.  This indicates that additional 
optimizations of this system may determine that mannitol addition could allow larger pore sized 
filters to remove parvoviruses from FDA regulated manufacturing processes. 
4.3.2. Qualitative shear stress effect on PPV flocculation  
The effect of shear stress on PPV aggregates was tested at different glycine 
concentrations.  Low, medium and high shear stress were applied to the formation of aggregates.  
As shown in Figure 4.3, virus removal under high shear stress was very low (<12%) at all the 
concentrations tested, indicating that the virus aggregates are fragile and can be broken by shear 
stress.  Due the fact that the aggregates are fragile, it is likely that tangential flow filtration could 
break the aggregates.  Therefore, dead-end microfiltration will need to be used after the virus 
flocculation step.  As shear stress decreased, virus removal increased. 
?
Figure 4.3.  Qualitative effect of shear stress on PPV flocculation.  PPV was flocculated with 
glycine.  % removal is defined in Eq. 4.2.  All data points are the average of three separate 
experiments and the error bars represent the standard deviation.  ???value of <0.05 as compared 
to the water control using Student’s t-test. 
 
The highest virus removal (82%) was achieved at low shear stress with 3.0 M of glycine 
(Figure 4.3).  We found that PPV aggregates can be recovered after high shear stress followed 
by low shear stress, as shown by a 66% removal by 3.0 M glycine (Figure 4.3).  Glycine at 3.0 M 
and 0.3 M showed higher virus removal than 1.0 M of glycine, indicating that virus flocculation 
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with glycine may work as a salting in-salting out process, where optimal conditions for 
aggregation are found at low and high concentration of the osmolyte. 
4.3.3. pH effect on PPV flocculation 
Alanine, glycine, mannitol and trehalose were used to explore the pH effect on PPV 
flocculation.  Since PPV has been found to be stable in the pH range 3 - 9 [72],  the pH was 
explored between 5 - 8 (Figure 4.4).  Osmolyte pH was changed in order to change the charge of 
the virus and increase virus aggregation.  The isoelectric point (pI) of parvovirus capsid has been 
tested and found to be ~5 [73].  When the pH of the zwitterionic amino acids solutions was close 
to the pI of the virus, virus removal was improved (Figure 4.4A).  In the presence of zwitterionic 
osmolytes, the neutrally charged virus prefers to aggregate.  As the virus becomes negatively 
charged above its pI, the virus surface experiences electrostatic repulsion.  The electrostatic 
repulsion between the charged virus particles likely decreases virus aggregation.  The increase in 
virus charge leads to greater interactions with water molecules, which tend to increase solubility.  
The neutral compounds, mannitol and trehalose, did not present a pH dependence behavior 
(Figure 4.4B), as shown for the zwitterionic amino acids.   
?
Figure 4.4.  pH effect on PPV flocculation with a micropore filter.  % removal is defined in Eq. 4.2.  
All data points are the average of three separate experiments and the error bars represent the 
standard deviation.  ?? value of <0.05 as compared to the water control using Student’s t-test. 
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Virus aggregation can be affected by different interactions of the virus with water and with 
the osmolytes.  These interactions include charge-charge, hydrogen-bonding, and hydrophobic 
interactions.  It has been found that sugars are able to fold proteins by a preferential exclusion 
model [74].  Sugars are excluded from the neighboring areas close to the proteins, leading to a 
preferential hydration shell around proteins and a strong inclination for hydrogen-bonding [75].  It 
is likely that the changes in pH in the zwitterionic osmolyte solutions increase the charge-charge 
repulsion of the virus particles and altered the water structure around the virus. However, the 
strong hydrogen-bonding interactions created by the addition of sugars and sugars alcohol 
cannot be affected by the changes in pH. 
4.3.4. Ionic strength effect on PPV flocculation  
Alanine and mannitol were used to study the ionic strength effect on PPV flocculation.  
These two osmolytes were chosen to test the difference between a zwitterionic molecule and a 
neutral molecule.  There is not clear evidence in the literature determining if zwitterionic 
molecules contributed to ionic strength [76-79], therefore we compared alanine and mannitol 
assuming alanine did and did not contribute to ionic strength.  For alanine, the same set of data 
was plotted twice (Figure 4.5), once assuming alanine did not contribute to the ionic strength and 
once assuming alanine did contribute to the ionic strength.  For alanine, virus removal decreased 
as ionic strength increased.  For mannitol, virus removal from 0.2 to 0.6 M NaCl did not display a 
clear trend.  In the range of 1.2–1.6 M of NaCl, virus removal decreased in a dose dependent 
manner (Figure 4.5).  The osmolytes, alanine and mannitol were viscous solutions at the 
concentration tested (1.0 M), due to the strong interactions between the solute and the solvent, 
leading to high solute particle movement resistance [80].  Disaccharides and monosaccharides 
have a tendency to increase the viscosity of protein solutions; however, the viscosity can be 
reduced with the addition of salts [75].  We also show that a small amount of NaCl added to a 1.0 
M mannitol solution greatly decreased the virus removal and aggregation.  The decrease in 
viscosity could play a role in this aggregation tendency (Figure 4.5). 
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Figure 4.5.  Ionic strength effect on PPV flocculation with a micropore filter.  Two assumptions 
were used to test the ionic strength effect of zwitteric alanine.  Ionic strength range of 0.0 - 0.6 M 
shows 1 M mannitol with the addition of 0 – 0.6 M NaCl, and alanine with the addition of 0 - 0.6 M 
NaCl and the assumption that alanine did not contribute to ionic strength.  Ionic strength range of 
1.2 - 1.6 M shows 1 M mannitol with the addition of 1.2 – 1.6 M NaCl, and alanine with the 
addition of 0 - 0.6 M NaCl and the assumption that alanine did contribute to ionic strength.  All 
data points are the average of three separate experiments and the error bars represent the 
standard deviation.  *p value of <0.05 as compared to the water control using Student’s t-test. 
 
Stellwagen and coworkers gave experimental evidence that zwitterions do not contribute 
to ionic strength.  They studied the effect of the zwitterion tricine in capillary electrophoresis.  The 
mobility of double-stranded DNA was expected to decrease with the square root of ionic strength, 
however, the mobility of the DNA was independent of the concentration added of the zwitterion 
tricine [78].  The study suggested that tricine does not contribute to the ionic strength of a 
solution.  However, other groups have looked at the charge distribution of zwitterions and 
assumed that zwitterions contribute to the ionic strength without experimental evidence [79].  
Comparing the two sets of data, mannitol had the same trend as alanine when alanine was 
assumed to contribute to ionic strength (Figure 4.5).  This is weak evidence that alanine does 
contribute to the ionic strength since it took a higher salt concentration for mannitol to have a 
similar trend as alanine.  The evidence is weak because the virus removal with a change in pH 
has different trends for alanine and mannitol (see Figure 4.4), so we do not have a basis to 
propose that the trends for ionic strength should be the same.  Further studies will be done to 
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clarify if alanine contributes to ionic strength of a virus solution.  It has been proposed that 
interactions between salts and amino acids in aqueous systems are affected by the nature of the 
salt and the length of the hydrocarbon chain of the amino acids [81].  It is probable that the 
distance between the two charges in alanine is far enough apart that they may contribute to the 
ionic strength of a solution, whereas the charges in tricine do not contribute [78]. 
4.3.5. Preferential PPV flocculation 
PPV was preferentially flocculated in the presence of osmolytes, whereas model proteins, 
BSA and lysozyme, were not, as shown in Figure 4.6.  BSA and lysozyme were chosen because 
they represent different protein sizes and charges.  Removal of proteins was very low in the 
presence of 1 M of mannitol and 1 M alanine (<5%).  PPV removal was high with osmolytes, 
80.2% with alanine, and 85.1%with mannitol.  Magnesium sulfate was used as a control 
flocculant to demonstrate that salts flocculated both PPV (98.6%) and other proteins, BSA 
(53.2%), and lysozyme (86.4%).  Osmolytes were not able to flocculate model host cells proteins, 
demonstrating that they are specific to our model virus.  Virus flocculation with osmolytes is a 
potential method to purify the viral products from host cell proteins. 
?
Figure 4.6.  Protein and PPV removal with a micropore filter.  All data points are the average of 
three separate experiments and the error bars represent the standard deviation. 
 
 
104 
?
In order to use preferential flocculation as a virus purification method, the virus needs to 
be recovered from the membrane surface.  We have recovered infectious virus from the 
membrane surface, but the recovery is currently low (?2%).  We continue to explore methods to 
recover the virus by changes in eluent composition, membrane material of construction, and 
backflushing. 
4.4. Conclusions 
Viral particles play an important role in reducing the incidence of infectious diseases and 
they show promise in decreasing the incidence of many other deadly diseases.  To overcome 
limitations of current purification methods for viral vectors and vaccines, like chromatography and 
filtration, we propose to use virus flocculation with osmolytes, followed by microfiltration.  A 
variety of osmolytes were screened in a high throughput manner to find compounds that promote 
flocculation of PPV.  We have discovered that glycine, alanine, sucrose, trehalose, and mannitol 
have the ability to remove >80% of PPV with a 0.2 μm microfiltration membrane, which is usually 
used to remove bacteria, not small viruses such as PPV.  The use of a micro-filter would increase 
the flux and decrease the transmembrane pressure of typical virus filters. 
Virus removal was improved by reducing the shear stress on the aggregates, by 
adjusting the pH close to the pI of the virus, and having a low ionic strength.  Our top removal 
was 96% of PPV in 3.0 M glycine at low shear stress and a pH of 5, without addition of NaCl.  
PPV aggregates formed by the addition of osmolytes are fragile and can be broken with moderate 
shear stress.  Adjusting the pH of the solution to the pI of PPV improved virus removal in 
zwitterionic amino acid solutions.  It is likely that virus aggregation increased when the net charge 
of individual virus particles is neutral.  The neutrally charged sugar and sugar alcohol tested did 
not change their aggregation propensity with a change in pH.  As total ionic strength increased, 
virus removal decreased.  This is likely due to the weakly hydrating sodium cation that is known 
to increase protein solubility. 
We demonstrated that osmolyte flocculation is specific to virus particles as compared to 
two model host cell proteins.  We propose that the specificity is due to high virus hydrophobicity.  
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Our past work on virus binding peptides concluded that both hydrophobicity and charge play a 
major role in the binding of porcine parvovirus [82-84].  Osmolytes are able to change how water 
molecules align around the virus.  We hypothesized that osmolytes are able to preferentially 
flocculate hydrophobic virus particles by strongly binding to water molecules, consequently 
depleting the hydration layer around the virus particles and stimulation of virus aggregation.  
Highly hydrophobic viruses flocculate in lower concentrations of osmolytes than the less 
hydrophobic proteins, providing for selective flocculation and purification.  
The aim of virus flocculation with osmolytes followed by microfiltration is to replace 
current unit operations used in virus purification, such as chromatography and nanofiltration.  If 
process integration is needed, a buffer exchange step before any chromatography column will be 
required, due to the high osmolytes concentration.  Further studies will need to be done in filter 
capacity and pressure-flux profiles for successfully commercialization of virus flocculation in 
osmolytes, along with recycling of the osmolyte solution. 
A major advantage of using osmolytes for virus flocculation, rather than salts or PEG, is 
that osmolytes have been used as excipients in the final formulation of some biotherapeutics.  We 
propose that virus flocculation with some osmolytes, including sugars, sugar alcohols and amino 
acids, followed by microfiltration could be used as an alternative process for virus purification.  
Our goal is to find an osmolyte that could be used as a platform purification for viral products. 
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Chapter 5  
Purification of Sindbis virus with osmolytes flocculation, 
followed by microfiltration1   
??????????????????????????????????????????????????????
?
1 ???? ???????????????????????????????????????????????????????????????????
?
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5.1. Introduction 
Viral diseases account for over 13 millions deaths per year.  Viral vaccines are the most 
effective method to prevent and control viral infections [1].  Currently, vaccines prevent around 
2.5 millions deaths per year [2].  There are two main reasons why vaccines are not able to offer a 
complete coverage: emerge of operational limitations on the supply side, and negative 
advertisements on the effects of vaccines on the consumption side [1].  As scientists, we can 
improve the operational limitations in the manufacturing process, but as society we should 
increase the awareness of the importance of vaccination.  Scientists are working together to 
develop safe and effective vaccines at a lab scale.  However, once the vaccine is ready, the 
speed of the manufacturing process of the vaccine needs to increase and the high costs involved 
in the manufacturing process need to decrease in order to have sufficient supplies for every 
nation [3, 4].  The improvement of current manufacturing processes could lead to the fast 
development of effective and economical vaccines. 
Vaccine manufacturing process is divided into upstream processes (USP) and 
downstream processes (DSP).  The vaccine antigen is produced in the USP.  The DSPs account 
for 70% of the overall cost of the production process [5, 6] and consist of the recovery and 
purification of the desired vaccine.  The elevated costs involved in the DSP stages are related to 
column chromatography and nanofiltration, each of which are highly used in the purification 
stages [7].  Chromatography is the predominant unit operation for virus purification.  However, it 
is not suitable for all types of viruses.  Conventional chromatography resins present limited 
diffusion for large virus particles, due the fact that virus particles have difficulties accessing the 
high internal surface area of these resins [8, 9].  Ultrafiltration has been used to purify virus 
particles as an alternative to chromatography.  However, the capacity of the membranes can be 
affected by fouling [10], leading to longer filtration time, high transmembrane pressure, and low 
flux through the membrane [5, 11].  Due to all the limitations of chromatography and ultrafiltration, 
we propose to use virus flocculation with osmolytes, followed by microfiltration as an alternative to 
current unit operations.  A micro-filter, typically used to retain bacteria and not viruses, would 
114 
?
increase the flux and decrease the transmembrane pressure as compared to ultra-filters. 
Osmolytes, which we propose as flocculants, are natural compounds found in the cells of 
many organisms, and their main function is to stabilize intracellular proteins against 
environmental stresses and maintain cell volume [12].  There are two types of osmolytes, 
protecting and denaturing.  Protecting osmolytes have the ability to fold proteins by structuring 
water and rearranging the water content around the protein.  Denaturing osmolytes have the 
opposite effect, they unfold the proteins by binding directly to the protein backbone [13].  In our 
previous studies, we have shown that protecting osmolytes, such as sugar alcohols and amino 
acids, preferentially flocculate a non-enveloped virus, porcine parvovirus (PPV), and our top 
osmolyte demonstrated a 96% removal in 3.0 M glycine (pH of 5) with a 0.2 ?m filter while leaving 
model proteins in solution [14].  In this study we propose to use protecting osmolytes to flocculate 
an enveloped virus, in our quest to create a platform approach to virus and vaccine purification for 
non-enveloped and enveloped viruses.  Both types of viruses possess a capsid made of multiple 
copies of identical protein subunits that enclose the genetic material.  The difference between 
enveloped and non-enveloped viruses is that the capsids of enveloped viruses are surrounded by 
a lipid bilayer, into which glycoproteins are incorporated.  We propose that the osmolyte 
flocculants are able to specifically flocculate hydrophobic non-enveloped and enveloped virus 
particles by depleting a hydration layer around the particles and subsequently cause virus 
aggregation.  We are attempting to establish that osmolytes can could be used as a platform 
purification for viral products. 
5.2. Materials and methods 
5.2.1. Materials 
The osmolytes, trimethylamine N-oxide (TMAO) dihydrate, glycine, betaine, D-alanine, D-
arginine, L-proline, L-serine, D-mannitol, sucrose, D-(+)-trehalose dihydrate, D-(+)-raffinose 
pentahydrate, and urea; and the salts, ammonium sulfate, sodium chloride (NaCl), magnesium 
sulfate, and magnesium chloride, at a purity of >98% were purchased from Sigma-Aldrich (St. 
Louis, MO).  Polyethylene glycol (PEG) (MW=12,000 Da), and albumin from bovine serum (BSA) 
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were also purchased from Sigma-Aldrich.  Cell culture reagents, phosphate-buffered saline (PBS, 
pH 7.2), 0.25% trypsin/EDTA, gentamicin reagent solution, and minimum essential medium 
(MEM) were purchased from Life Technologies (Carlsbad, CA).  MTT Assay reagents, thiazolyl 
blue tetrazolium bromide (MTT), sodium dodecyl sulfate (SDS) and hydrochloric acid (HCl) were 
purchased from VWR (Radnor, PA).  Tryptose phosphate broth (TPB) for cell culture was also 
obtained from VWR.  Lysozyme from chicken egg white was purchased from EMD Millipore 
(Billerica, MA).  All solutions were prepared with NanoPure water (Thermo Scientific, Waltham, 
MA, resistance >18 M?), and then filtered with a 0.2 ?m syringe filter (Nalgene, Rochester, NY). 
5.2.2. Cell propagation, virus production and titration 
Baby hamster kidney (BHK-21) cells and Sindbis virus heat resistant strain (SVHR) were 
a gift from Dr. Raquel Hernandez at North Carolina State University.  BHK-21 cells were grown at 
37°C, 5% CO2 and 100% humidity in MEM supplemented with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals, Norcross, GA), 5% TPB, and 1% gentamicin, as described earlier [15].  BHK-
21 cells were propagated every day and split 1:3. 
SVHR was propagated as described previously [15].  Briefly, BHK-21 cells were 
incubated for 24 hours, and then infected with 1 ml of SVHR at a MOI between 10-50 pfu/cell 
diluted in PBS.  After 1.5 hours, 9 ml of media was added, and the infected cells were incubated 
until cytopathic effects were observed.  Virus was clarified, and the supernatant virus was stored 
in 10% glycerol at -80°C.  
The cytopathic effect (CPE) of SVHR in BHK-21 cells was quantified with either a cell 
viability assay, the MTT assay or a TCID50 virus titration assay.  The MTT assay is a colorimetric 
assay that measures enzymatic activity in active mitochondria and can be used to measure CPE.  
BHK-21 cells were seeded in 96-well plates at a density of 1.1 x 105 cell/ml (MTT assay) or 5.0 x 
105 cell/ml (TCID50 assay).  After 24 hours, cells were infected with BHK-21 in quadruplicate and 
5-fold serial dilutions were done across the plate.  For the MTT assay, the MTT solution was 
added after 2 days, followed by the solubilizing agent after 4 hours.  Plates were read on a 
Synergy Mx microplate reader (BioTek, Winooski, VT) at 550 nm, between 18-24 hours later.  
116 
?
The 50% infectious dose (MTT50) was stated as the virus dilution that achieved 50% of the 
uninfected cell absorbance.  The value was defined on a per milliliter basis (MTT50/ml) titer.  For 
the TCID50 assay, plates were read manually after 2 days.  Wells were considered to have CPE 
when there was a loss of contact between the cells.  Wells were scored by the Karber method 
[16].  
5.2.3. Flocculation and filtration 
Virus and protein flocculation was conducted as described previously [14].  Briefly, 30 ?l 
of SVHR at 106 TCID50/ml (MTT50/ml) or 20 mg/ml of BSA or lysozyme in PBS were incubated 
with 720 ?l of an osmolyte solution for 2 h at room temperature.  As a control, NanoPure water 
was incubated with SVHR at 106 TCID50/ml (MTT50/ml) or 20 mg/ml of BSA or lysozyme in PBS.  
Flocculated virus particles or protein particles were filtered with a 0.2 ?m, 96-well filter plate 
(Millipore, Billerica, MA) at 200 xg, 4°C for 20 minutes in a Sorvall ST16R Centrifuge (Thermo 
Scientific, Pittsburgh, PA).  Virus samples before and after filtration were titrated as described in 
Section 2.2.  Protein sample absorbance before and after filtration was measured on a Synergy 
Mx microplate reader at 280 nm.  Percent of protein or virus removal was calculated with Eq. 5.1, 
????????? ? ?? ? ??????? ? ???      (5.1) 
where ???is the concentration of infectious virus or protein after filtration, ?? is the concentration of 
infectious virus or protein before filtration. 
5.2.4. Effect of pH and ionic strength 
The osmolytes betaine, proline, and mannitol at 0.3 M were tested for their ability to 
aggregate and flocculate SVHR particles at different pH levels.  The pH of the osmolyte solutions 
was adjusted by the addition of HCl or NaOH.  The osmolytes proline and mannitol, both of them 
at 0.3 M, were chosen to study the ionic strength effect.  For both osmolytes, 0.2 M - 0.6 M of 
NaCl was added to the osmolyte solution. The ionic strength was calculated with Eq. 5.2, 
? ? ?? ? ? ?????? ???        (5.2) 
where ?? is the concentration of ion ?, and ?? is the charge of ion ?. 
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Virus samples were flocculated and filtered as described in Section 5.2.3.  Samples 
before and after filtration were titrated as described in Section 5.2.2 and % virus removal was 
calculated with Eq. 5.1.  
5.3. Results and discussion 
Sindbis, our enveloped model virus, is a virus from the ??????????? family. It is one of the 
smallest enveloped viruses, with a diameter of between 60-70 nm, is a single-stranded, RNA 
virus, with an icosahedral capsid [17].  It is a model virus for eastern and western equine 
encephalitis viruses [18] and hepatitis C virus.  Purification and removal of Sindbis virus has been 
done with a combination of centrifugation and chromatography unit operations [19-21].  However, 
these methods have shown to inactivate the virus by 2 logs due to acidic wash buffers [20].  In 
this study, we propose virus flocculation in osmolytes as a new purification method.  The goal is 
to find an osmolyte that will not inactivate the virus and can be used as a global flocculant. 
5.3.1. Flocculation of SVHR with osmolytes, PEG and salts 
A variety of osmolytes were screened to demonstrate their ability to flocculate SVHR 
(Figure 5.1).  The salts magnesium sulfate, magnesium chloride and PEG were used as positive 
controls.  Osmolytes were selected in part from our results of a previous study on osmolyte 
flocculation of a non-enveloped virus [14].  Salts were selected as positive controls since they 
have been used to flocculate enveloped viruses, like the vaccinia virus and the cowpox virus; and 
non-enveloped viruses, like bacteriophages [22, 23], enteroviruses [22], and poliovirus [24, 25].  
PEG was also chosen as a positive control, since it has been used as a flocculent to purify virus 
particles, such as bacteriophages [26], adenovirus [27], and hepatitis A [28].  Many osmolytes, 
such as the amino acid proline, the N-oxide betaine, and the neutral molecules sucrose, 
trehalose, raffinose, and mannitol were able to flocculate SVHR and demonstrate a high % of 
virus removal (>80%) at all the concentrations tested. 
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Figure 5.1.  High-throughput screening of osmolytes as virus flocculants.  A variety of osmolytes 
were compared to the positive control salts and PEG and the negative controls, Tris, and water 
for flocculation of SVHR using a 0.2 ?m micropore filter.  80% removal was used as the cut-off to 
pursue testing.  % removal is defined in Eq. 5.1.  All data points are the average of three separate 
experiments and the error bars represent the standard deviation. 
 
The osmolytes urea and glycine, showed a >80% virus removal at low concentrations, 
but at high concentrations, they inactivated SVHR particles (Table 5.1).  We confirmed virus 
inactivation by testing the virus titer of each flocculating solution prior to filtration and comparing 
to the virus titer of the water control solution.  Glycine at 3.0 M and 1.0 M; and urea at 3.0 M 
reduced the virus titer by > 1 LRV, inactivating the virus prior to filtration (see Table 5.1).  
Osmolytes, such as arginine and serine and the salts sodium chloride and ammonium sulfate 
were also tested for virus flocculation and they were found to inactivated SVHR (> 1 LRV) at all 
the concentrations tested (see Table 5.1).  
Urea at high concentrations has been shown to inactivate enveloped viruses, such as 
hepatitis B and influenza [29, 30], likely due to the fact that urea destabilizes viral proteins.  
Arginine showed SVHR inactivation of ~2 logs.  This osmolyte has been shown to inactivate other 
enveloped viruses, such as influenza virus and the herpes simplex virus [31, 32].  Arginine has 
been proposed to replace the low pH step that can damage antibody products during viral 
clearance processes [32].  The mechanism of inactivation is not clear yet, but it has been 
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suggested arginine binds to proteins without denaturing them [31, 32].  In this study, we focused 
on flocculants that show high percent removal and did not inactivate SVHR. 
Table 5.1.  LRV compared to water control 
Flocculant log10(MTT50/ml) LRVa 
3.0 M GLY 2.97 +/- 0.05 1.22b 
1.0 M GLY 2.62 +/- 0.05 1.57b 
0.3 M GLY 3.46 +/- 0.68 0.74 
1.0 M ALA 3.62 +/- 0.07 0.58 
0.3 M ALA 4.09 +/- 0.13 0.11 
1.0 M ARG 2.22 +/- 0.09 1.97b 
0.3 M ARG 2.62 +/- 0.06 1.57b 
3.0 M BET 4.88 +/- 0.19 0.00 
1.0 M BET 4.99 +/- 0.38 0.00 
0.3 M BET 4.92 +/- 0.09 0.00 
3.0 M PRO 4.50 +/- 0.24 0.00 
1.0 M PRO 4.85 +/- 0.32 0.00 
0.3 M PRO 5.32 +/- 0.10 0.00 
3.0 M SER 2.23 +/- 0.28 1.96b 
1.0 M SER 2.25 +/- 0.19 1.95b 
0.3 M SER 2.49 +/- 0.32 1.71b 
3.0 M TMAO 3.75 +/- 0.17 0.44 
1.0 M TMAO 4.24 +/- 0.15 0.00 
0.3 M TMAO 4.47 +/- 0.15 0.00 
3.0 M UREA 2.87 +/- 0.17 1.33b 
1.0 M UREA 3.97 +/- 0.14 0.22 
0.3 M UREA 4.94 +/- 0.11 0.00 
1.0 M SUC 5.08 +/- 0.21 0.00 
0.3 M SUC 4.82 +/- 0.44 0.00 
1.0 M TRE 4.44 +/- 0.05 0.00 
0.3 M TRE 4.79 +/- 0.15 0.00 
0.3 M RAF 4.39 +/- 0.07 0.00 
1.0 M MAN 5.05 +/- 0.18 0.00 
0.3 M MAN 5.50 +/- 0.23 0.00 
3.0 M S. CHL 2.03 +/- 0.23 2.16b 
1.0 M S. CHL 1.83 +/- 0.40 2.36b 
0.3 M S. CHL 3.13 +/- 0.56 1.06b 
3.0 M A. SUL 3.07 +/- 0.02 1.12b 
1.0 M A. SUL 2.40 +/- 0.12 1.79b 
0.3 M A. SUL 1.71 +/- 0.09 2.49b 
3.0 M M. SUL 3.96 +/- 0.81 0.23 
1.0 M M. SUL 4.60 +/- 0.26 0.00 
0.3 M M. SUL 3.10 +/- 0.11 1.00 
3.0 M M. CHL 3.95 +/- 0.10 0.24 
1.0 M M. CHL 4.36 +/- 0.14 0.00 
0.3 M M. CHL 4.38 +/- 0.32 0.00 
20% PEG 3.76 +/- 0.23 0.43 
10% PEG 3.88 +/- 0.10 0.32 
5% PEG 3.81 +/- 0.18 0.38 
TRIS 4.68 +/- 1.74 0.00 
H2O 4.20 +/- 0.68 0.00 
aLRV was calculated with Eq. 5.1, where ???is the concentration of infectious virus in the presence of the flocculant and ?? 
is the concentration of infectious virus in the presence of water.  bFlocculants that reduced the virus titer by > 1 LRV 
 
The advantage of osmolyte over salt flocculation is that high concentrations of salts (3 M 
& 1 M) were required to flocculate virus particles, whereas low concentrations of osmolytes (0.3 
M) were enough to flocculate SVHR particles (Figure 5.1).  The positive control, PEG, did not 
reach a high percent removal (>80%), likely due to the fact that PEG flocculation requires low 
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temperatures and long incubation times [27, 28].  In our previous studies with the non-enveloped 
virus PPV, we report higher virus removal with the amino acid alanine than with the amino acid 
proline [14].  In this work, proline at all the concentrations tested was able to aggregate and 
flocculate the enveloped virus, SVHR.  This is likely due the fact that proline is more soluble in 
water than alanine and has the ability to structure more water molecules around SVHR that 
alanine.  The osmolytes that achieved the highest percent removal were tested for their ability to 
aggregate and flocculate virus particles at different pH values and ionic strengths. 
5.3.2. pH effect on SVRH flocculation 
The osmolytes betaine, mannitol and proline were used to study the pH effect on SVHR 
flocculation.  Osmolyte solution pH was adjusted in order to change the overall charge of the 
virus.  SVHR has been show to be stable in the pH range of 5-8 [33], so a pH range of 5.5 to 8.5 
was selected to study the pH effect on SVHR flocculation (Figure 5.2).  The highest percent 
removal occured near the isoelectric point (pI) of Sindbis virus, which has been tested and found 
to be ~ 4.2 [34].  At pH values close to the pI of the virus, the overall charge became neutral and 
virus aggregation increased.  On the other hand, as the pH value was increased, the negative 
charge on the virus increased, and virus removal decreased, likely due to electrostatic repulsion 
between the virus particles. 
?
Figure 5.2.  pH effect on SVHR flocculation with a micropore filter.  % removal is defined in Eq. 
5.1.  All data points are the average of three separate experiments and the error bars represent 
the standard deviation. 
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The neutral molecules mannitol and betaine showed a higher removal than the zwitterion, 
proline, at pH 7.5 and 8.5, probably due the fact that the increase of charge on SVHR particles 
was further enhanced by the charged proline molecule, thus increasing the charge repulsion of 
the SVHR particles.  In our previous study, we showed that changes in pH in the zwitterionic 
osmolytes glycine and alanine can increase the charge-charge repulsion of PPV particles.  This 
behavior was not seen with the sugar and sugar alcohol osmolytes, likely because neutral 
molecules are able to promote virus flocculation by strong hydrogen-bonding interactions; and not 
charge-charge interactions [14].  Zwitterion and neutral osmolytes likely have the same manner of 
function with pH changes on virus aggregation with non-enveloped and enveloped viruses.  
5.3.3. Ionic strength effect on SVHR flocculation 
The zwitterion, proline and the neutral molecule, mannitol were used to investigate the 
ionic strength effect on SVHR flocculation.  Some researchers have suggested that zwitterions do 
contribute to the ionic strength of a solution and other groups have demonstrated the opposite 
[35-37].  Stellwagen ?????. have shown with experimental data that zwitterions do not contribute to 
the ionic strength of a solution containing DNA [37].  They used capillary electrophoresis to 
determine if the zwitterion tricine contributed to the ionic strength of a solution.  DNA mobility was 
expected to decreased, as the square root of the ionic strength decreased.  However, there was 
not a dependency on the mobility of the DNA with respect to the concentration of the zwitterion 
tricine [37].  This study suggested that the zwitterion tricine does not contribute to the ionic 
strength of a solution.  Other research groups without experimental evidence have argued that 
charges on zwitterionic molecules are separated with enough distance that zwitterionic molecules 
do contribute to the ionic strength of a solution [35, 36].  In this study, we assumed that the 
zwitterionic proline does not contribute to the ionic strength of a solution.  SVHR removal did not 
change with an increase in ionic strength for the osmolytes, proline and mannitol (Figure 5.3).  
We suggested that besides hydrophobic interactions, charge-charge and hydrogen bonding 
interactions also affect virus aggregation.  We propose that charge-charge interactions are 
predominant with zwitterionic osmolytes, and hydrogen-bonding interactions are predominant with 
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neutral osmolytes.  It is likely that the strength of electrostatic interactions and hydrogen bonding 
interactions are not appreciably affected by low concentration of the weak chaotropic agent, 
NaCl.  For our water control, virus removal increased as we increased the concentration of salt, 
likely due to a salting-in and salting-out mechanism.  As we increased salt concentration, we 
decreased virus solubility, and consequently we increased virus aggregation.  
?
Figure 5.3.  Ionic strength effect on SVHR flocculation with a micropore filter.  % removal is 
defined in Eq. 5.1.  All data points are the average of three separate experiments and the error 
bars represent the standard deviation. 
 
In our previous studies, we showed that PPV flocculation, and consequently PPV 
removal, was lower with the neutral molecule mannitol than with the zwitterion alanine, at low 
concentrations of ionic strength (0 to 0.6 M), where we assumed that alanine did not contribute to 
ionic strength [14].  It is likely that NaCl affected the hydrogen bonding interactions between 
mannitol and water molecules with PPV flocculation and not SVHR.  Probably, the hydrophobic 
proteins in the enveloped virus promote strong hydrogen bonding between mannitol and water 
molecules, which are not easy to disrupt.  More studies need to be done assuming that zwitterion 
proline does contribute to ionic strength with the enveloped virus, so that both assumptions can 
be compared for the two model viruses, PPV and SVHR.  We have shown both assumption with 
the zwittherions molecules in our PPV flocculation studies [14] and the same methodology will be 
followed for our SVHR flocculation future studies.  
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5.3.4. SVHR preferential flocculation with osmolytes 
The model proteins bovine BSA and lysozyme were used to demonstrate the effect of 
preferential flocculation of osmolytes with virus particles (Figure 5.4).  These two proteins were 
selected due to the difference in their physical properties, such MW, stokes radius, and isoelectric 
point (See Table 5.2).   
Table 5.2.  Physical properties of BSA and lysozyme 
Protein MW (kDa) Stokes radius (nm) Isoelectric point Reference 
BSA 66.4 3.5 4.7 [38-40] 
Lysozyme 14.3 2.1 11.3 [41, 42] 
 
BSA and lysozyme removal was very low in the presence of osmolytes (< 23%) as 
compared to the salt, magnesium sulfate (54% for BSA and 87% for lysozyme), indicating that 
salts, and not osmolytes, enhance protein flocculation.  The osmolytes mannitol and proline at 0.3 
M and the salt magnesium sulfate at 3.0 M were able to flocculate SVHR particles.  High 
concentrations of salts compared to osmolytes were required to achieved virus flocculation and 
consequently high virus removal (Figure 5.1 & 5.4).  SVHR was preferentially flocculated in the 
presence of low concentration of osmolytes, whereas BSA and lysozyme were not.  Osmolyte 
flocculation is specific to virus particles, making this a method to purify the virus particles from 
protein contaminants. 
?
Figure 5.4.  SVHR and protein removal with a micropore filter.  All data points are the average of 
three separate experiments and the error bars represent the standard deviation. 
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5.4. Conclusions 
Virus purification is essential in vaccine manufacturing.  Current unit operations, such as 
chromatography and nanofiltration present several drawbacks.  In this study, we have shown that 
protecting osmolytes, like proline and mannitol were able to aggregate and flocculate the 
enveloped virus, SVHR and demonstrate >80% virus removal with a 0.2 ?m filter.  Our top 
removal was 98.1% of SVHR in 0.3 M mannitol.  In our previous studies, mannitol at the same 
concentration was able to aggregate and flocculated a non-enveloped virus, PPV (81% removal) 
[14].  This osmolyte flocculant structures water molecules around the hydrophobic enveloped or 
non-enveloped virus, leading to a decreased hydration layer around the virus and increasing 
hydrophobic interactions between virus particles.  Virus flocculation with mannitol, followed by 
microfiltation could be used as a global process for virus purification.  
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Chapter 6  
Biocompatibility studies of soft-template mesoporous carbons1  
  
??????????????????????????????????????????????????????
?
1?The material contained in this chapter was previously published in Applied Materials and 
Interfaces. Reprinted with permission from, Gencoglu, M. F., Spurri, A., Franko, M., Chen, J., 
Hensley, D. K., Heldt, C. L., Saha, D. Biocompatibility of Soft-Templated Mesoporous Carbons. 
Applied Materials and Interfaces. 2014;6:15068-15077. Copyright 2014 American Chemical 
Society.?
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6.1. Introduction 
Carbon-based materials have attracted great attention in biomedical and biological fields 
owing to their stability, chemical inertness, mechanical strength and high surface area [1].  
Morphologically, carbon-based materials can be classified into two distinct categories, nano 
carbons and non-nano carbons.  Within the nano carbon variety, carbon nanotubes (CNTs) were 
considered to be an excellent material and examined several times for their characteristic 
biocompatibility [2, 3].  Although the results from different research groups appeared to be 
conflicting and counter-intuitive [4], it has been almost universally accepted that CNTs are toxic 
and their toxicity can be related to an adverse dermal [5], respiratory [6, 7], pulmonary [8, 9], or 
cellular [10] response. It was also suggested that toxicity of CNTs vary widely with their degree of 
agglomeration, functionalization and catalyst contents [2-4].  Besides CNTs, fullerenes also 
demonstrated characteristic toxicity [11].  On the other hand, non-nano carbons appeared to be 
much more benign.  Diamond-like carbon (DLC) was employed as an attractive candidate for 
implants purposes, and it did not show significant toxic behavior [12-14].  Activated carbon is 
another type of non-nano carbon and has long been used for drug overdose and accidental toxin 
ingestion without any sign of toxicity [15, 16].  Plenty of evidence has come to light that any nano-
sized particle may bear potential health hazards [17], an approach towards building a non-nano 
carbon-based drug carrier might avoid any potential health risk in the first place.  
Soft-templated mesoporous carbon is a relatively newer variety of synthetic, non-nano 
and porous carbon that finds its key distinct features in controlled large pore accessibility and 
tunability of pore textures.  Although mesoporous carbon has already established its role in the 
field of environmental applications, gas separation and storage, and energy harvesting, biological 
applications of this material are a relatively new and growing field.  Synthesis of this material can 
employ different classes of amphiphilic surfactants for templating purposes, the role of which is 
very similar to that of silica in the case of hard-templating (i.e., to dictate mesoporosity).  
Typically, the crosslinked phenolic carbon precursors are held together by the micelles of 
amphiphilic surfactants through hydrogen bonding and translate the mesoporosity to the carbon 
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matrix upon pyrolysis.  Figure 6.1 shows the general schematic of fabricating an ideal 
mesoporous carbon from soft templates.  Over time, both synthetic and natural carbon precursors 
were employed to fabricate mesoporous carbons by soft-templating.  
 
Figure 6.1.  Generalized correlation of synthesizing an ideal mesoporous carbon from phenolic 
precursor via soft-templating.  In this schematic, we have employed resorcinol-formaldehyde 
cross-linked resin as carbon precursor and a tri-block copolymer, [PEO]x-[PPO]y-[PEO]z (PEO: 
Polyethylene oxide; PPO: Polypropylene oxide) as soft-template.  For better visualization of 
micelles within phenolic resin and transformation of micellar regions onto mesopores, we have 
incorporated an imaginary circular sliced section of polymer composite and the resultant carbon 
upon carbonization and activation. 
?
132 
?
Recently published literature by part of our group and other researchers demonstrated 
that mesoporous carbon could be employed as a unique and controlled drug delivery vessel.  
Saha et al. reported successful controlled release of four model drugs, captopril [18, 19], 
ranitidine hydrochloride [19], furosemide [19], and antipyrine [20] from mesoporous carbons, 
aimed towards oral drug delivery.  Ibuprofen [21, 22], indomethacin [22], and lovastatin [23] were 
three other drugs that were employed to examine the performance of mesoporous carbon as drug 
delivery vehicles.  Besides oral drug delivery, nanosized or thin film mesoporous carbons were 
also successfully employed for controlled and targeted release of anticancer drugs, namely, 
doxorubicin [24], camptothecin [25], and mitoxantrone [26], aimed towards blood plasma or 
transmembrane delivery. 
Owing to the disadvantages of mesoporous silica or metal-organic frameworks (MOFs) 
as drug delivery vehicles [19, 27-31], mesoporous carbon could be a better choice as a porous-
media-based drug delivery system, in addition to its high material tunability.  Although there are 
several reports on mesoporous carbons as drug delivery vehicles, biocompatibility studies of this 
material are quite handful and not universal.  Karavasili et al.[22] performed toxicity and cellular 
uptake studies of mesoporous carbons with human colon carcinoma (Caco-2) cells that revealed 
no significant toxicity or abnormal change in cell morphology in contact with mesoporous carbons.  
Zhao et al.[23] examined the cytotoxicity of uniform mesoporous carbon spheres with the same 
type of cells (Caco-2) and revealed no cytotoxicity.  Zhu et al.[24] and Kim et al.[32] confirmed the 
null toxicity of nanosized mesoporous carbon particles on cervical cancer (HeLa) cells.  Fang et 
al.[33] reported similar evidence of zero toxicity of mesoporous carbon with human 
nasopharyngeal epiclermal carcinoma (KB) cells.  Gu et al.[25] reported on the in vitro cytotoxic 
behavior of camptothecin loaded mesoporous carbon, but they did not report the toxicity studies 
of pristine carbons.  Although the past literature confirmed zero to minimal cytotoxicity of 
mesoporous carbons, these studies did not verify other parameters of biocompatibility, including 
the role of pore textural properties on the degree of biocompatibility. 
In this collaborative research, we have synthesized soft-templated mesoporous carbon 
from two phenolic precursors, resorcinol and phloroglucinol and two triblock copolymers, Pluronic 
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F127 and 17R4, as soft templates along with post-synthetic activation to improve the pore textural 
properties.  We have incorporated these materials with varying porosity in the studies of cell 
toxicity with HeLa cells, cell growth with fibroblast cells, blood protein adhesion and hemolysis.  
To the best of our knowledge, this is the first report on the detailed biocompatibility studies of 
mesoporous carbons or any nanoporous carbon in general.  These mesoporous carbons were 
fabricated by using varying synthesis conditions and contain different degrees of porosity so that 
the results of the study can be analyzed and interpreted in a broad platform. 
6.2. Materials and methods 
6.2.1. Materials synthesis 
First, 50 g resorcinol and 40 g Pluronic F127 were dissolved in a mixture of 400 ml of 
water/20 ml of ethanol with 60 ml of HCl (6 M) for 1 h 30 min.  After that, 48 ml of formaldehyde 
as a cross-linking agent was added and stirred for 2 h until the polymer layer settled to the bottom 
with the solvent on top.  The polymer layer was separated and carbonized in a tube furnace in a 
N2 flow from room temperature to 400 °C at a rate of 1 °C/min, and from 400 °C to 1000 °C at a 
rate of 2 °C/min; the final temperature was maintained for 15 min, followed by cooling to room 
temperature in the same N2 flow.  To perform the activation, we mixed this material with solid 
KOH in a 1:3 ratio, heated the mixture in the tube furnace in a N2 flow from room temperature to 
1000 °C at a rate of 10 °C/min, and cooled the mixture in the same N2 flow.  The activated and 
inactivated are termed ???? and ????, respectively.  To synthesize another material, we mixed 
100 g phloroglucinol and 140 g Pluronic 17R4 in a mixture of 320 ml of water/480 ml of ethanol in 
the presence of 60 ml HCl (6 M), followed by addition of 96 ml of formaldehyde. The polymer was 
collected in a similar fashion and carbonized with the same protocol.  This material was named 
????.  
6.2.2. Material characterization 
????, ???? and ???? were characterized with pore textural properties in a 
Quntachrome Autosorb iQ (Boynton Beach, FL) by N2 adsorption-desorption at liquid N2 
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temperature (77 K) and CO2 adsorption-desorption at 273 K.  Brunauer–Emmett–Teller (BET) 
specific surface area and pore size distribution by nonlocal density functional theory (NLDFT) 
were calculated by using the instrument’s built-in software.  High-resolution transmission electron 
microscopic (TEM) images were obtained in a Carl Zeiss Libra 120 TEM (Thornwood, NY) 
operating at 120 kV.  The samples were dispersed in ethanol at about 0.5 wt % concentration and 
ultrasonicated for 5 min before being drop-casted onto an amorphous carbon (~20 nm in 
thickness) coated TEM grid (Ted Pella).  Scanning electron microscope (SEM) images of pure 
mesoporous carbons samples were obtained in a Carl Zeiss Merlin SEM operating at 30 kV.  No 
additional samples preparation protocol was employed for SEM images; the as-received samples 
were directly inserted into the sample holder for image capturing.  The energy-dispersive X-ray 
spectroscopy (EDXS) results were obtained with a system from Bruker Nano GmbH using a 
XFlash detector 5030.  The analysis was conducted with Bruker’s Quantax Esprit Hypermap 
mode.  The elements were selected using the automatic and find modes.  Oncea map was 
obtained, a 25 ?m area of interest was selected for the map data results so an average could be 
obtained.  The interactive standards were set during the quantify method.  The SEM high voltage 
was set to 30 kV, and the stage was tilted 30° to help alleviate the problem of absorption of X-
rays by the rough surface.  Sample thickness varied from 10 to 100 ?m.  The SEM stage holder 
and tweezers were cleaned with isopropyl alcohol and clean wipes. Fresh carbon tape was 
employed to mount the samples. 
6.2.3. Cytotoxicity  
HeLa cells (H1HeLa, CRL1958) were purchased from ATCC (Manassas, VA) and 
propagated in HeLa media, which consisted of minimum essential medium (MEM) (Life 
Technologies, Carlsbad, CA) supplemented with 5 % fetal bovine serum (FBS) (Atlanta 
Biologicals, Norcross, GA) and 1 % penicillin/streptomycin (pen/strep) (Life Technologies, 
Carlsbad, CA).  The cells were propagated at 37 °C, 5 % CO2 and 100 % humidity.  HeLa cells 
were seeded in a 96-well plate at a density of 8x104 cell/ml and 100 μL cells per well.  Stock 
solutions were prepared with 500 μg/ml of mesoporous carbon samples in HeLa media and 
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sonicated for 20 min in a Misonix XL-2000 Ultrasonic Probe Sonicator (Sonics & Materials, 
Newtown, CT).  Samples ranging from 50-450 μg/ml were prepared from the stock solution.  All 
the samples, including the stocks were sonicated in an Ultrasonic Water Bath (VWR, West 
Chester, PA) for 20 min.  Samples were added to the cells after 24 h at a volume of 25 μL. Cell 
activity was measured after 5 days by the conversion of the MTT tetrazolium salt (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; VWR, Radnor, PA) to its formazan form 
and was performed according to previous studies [34].  Percent survival was calculated with Eq. 
6.1: 
?????????? ? ? ????????? ? ???       (6.1) 
where Amc, and Amock were the absorbance of the mesoporous carbon (mc) and the mock 
media (mock), respectively. 
6.2.4. Cell viability 
Fibroblast (NIH/3T3, CRL1658), purchased from ATCC were propagated in fibroblast 
media, which consisted of Dulbecco’s modified eagle medium (DMEM) (Life Technologies, 
Carlsbad, CA) supplemented with 5 % FBS and 1 % pen/strep.  Fibroblast cells were grown at 37 
°C, 5 % CO2 and 100 % humidity.  Mesoporous carbon samples at 100 μg/ml in fibroblast media 
were sonicated for 20 min in a Misonix XL-2000 Ultrasonic Probe Sonicator.  Samples were 
added to 24-well plates at a volume of 100 μl/well.  After the samples were added, fibroblast cells 
were seeded on the mesoporous carbon samples at a density of 2.5x105 cells/ml and 500 μl per 
well.  Cells were incubated with the mesoporous carbon samples from 1 to 4 days.  Cell viability 
was measured with a trypan blue exclusion assay.  After the media were removed, 200 μl of 0.25 
% trypsin/EDTA (Life Technologies Carlsbad, CA) was added to detach cells from the well and 
the mesoporous carbon.  Then 200 μl of fibroblast media was added to inactivate the trypsin.  
Next, 40 μl of trypan blue stain (0.4 %) (Life Technologies, Carlsbad, CA) was added to the cells 
and the viable and non-viable cells were counted in a hemocytometer.  Trypan blue is excluded 
from cells with an intact cell membrane, and these cells are assumed to be viable.  Percent 
viability was calculated with Eq. 6.2: 
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??????????? ? ?? ? ????????? ? ???       (6.2) 
where Ndc and Ntc were the number of dyed cells (dc) and total cells (tc), respectively. 
6.2.5. Hemolysis test 
Human blood samples for the hemolysis test were obtained from a voluntary donor at the 
Portage Health Clinic at Michigan Technological University.  All work was performed in a certi?ed 
Biosafety Level 2 laboratory with approval from the Internal Review Board (IRB).  The hemolysis 
test was conducted as stated by Fan et al.[35].  Briefly, the blood sample was collected in tubes 
containing EDTA and diluted 10-fold in a saline solution (0.9% NaCl).  The diluted blood was 
centrifuged at 1500 rpm for 10 min in an Accu SpinTM 400 centrifuge (Thermo Fisher Scientific, 
Waltham, MA).  The upper phase was removed, and the packed erythrocytes were washed three 
times with saline solution.  Packed erythrocytes were diluted 2 v/v % in saline solution.  Stock 
mesoporous carbon samples of 500 μg/ml were prepared in saline solution and sonicated for 20 
min in a Misonix XL-2000 Ultrasonic Probe Sonicator.  Four samples ranging from 100-500 μg/ml 
were prepared from the stock solution and sonicated in an ultrasonic water bath for 20 min.  After 
sonication, 0.45 ml of diluted erythrocytes were added to 0.45 ml of carbon sample and 
equilibrated at 37 °C.  Diluted erythrocytes were also added to NanoPure water (Thermo 
Scientific, Waltham, MA, resistance >18 M?; positive control) and to saline solution (negative 
control).  After 1 h, samples were centrifuged at 1500 rpm for 10 min.  The supernatant was 
removed and the absorbance was measured on a Synergy Mx microplate reader (BioTek, 
Winooski, VT) at 545 nm.  Percent hemolysis was calculated with Eq. 6.3: 
?? ???????? ? ?????????????????? ? ???       (6.3) 
where Amc, Aneg, Apos, were the absorbance of the mesoporous carbon (mc), the negative 
control (neg) and the positive control (pos), respectively. 
6.2.6. Protein adsorption 
Albumin from bovine serum (BSA) and fibrinogen from bovine plasma, purchased from 
(Sigma-Aldrich, St. Louis, MO), were diluted in phosphate-buffered saline (PBS, pH 7.2) (Life 
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Technologies, Carlsbad, CA) to a final concentration of 1 mg/ml.  The protein solutions were 
incubated with 0.0025 g of mesoporous carbon samples for 2 h at 37 °C.  Protein absorbance 
before and after contact with mesoporous carbon samples was measured on a Synergy Mx 
microplate reader at 280 nm.  The difference between the concentration before and after 
incubation with the carbon samples was determined as the concentration adsorbed on the 
mesoporous carbon samples. 
6.2.7. Imaging of cell growth of mesoporous carbon materials 
Cell growth on mesoporous carbon samples was done in a similar way as Correa-Duarte 
et al.[36].  Fibroblast cells were seeded on mesoporous carbon samples as described in Section 
6.2.4.  After 3 days, the cells attached to mesoporous carbon samples were scrapped out of the 
plates and placed into centrifuge tubes.  Samples were centrifuged at 1500 rpm for 10 min in a 
Sorvall ST16R Centrifuge (Thermo Fisher Scientific, Waltham, MA) and washed 3 times with 500 
μl of PBS.  Samples were fixed with 500 μl of 2.5 % glutardehyde (Sigma-Aldrich, St. Louis, MO) 
in 0.1 M sodium cacodylate (Sigma-Aldrich, St. Louis, MO), pH 7.4, for 2 h at 4 °C.  After several 
washes with 0.1 M sodium cacodylate, samples were dehydrated with ethyl alcohol (Pharmco-
Aaper, Brookfield, CT) in series (25%, 50%, 75%, 95%, 100%, 100%) for 10 min at each step.  
Samples were chemically dried in 1,1,1,3,3,3-Hexamethyldisilazane (HMDS) (Thermo Fisher 
Scientific, Waltham, MA), in series at 50% and 100% for 10 min at each step and placed 
overnight in a fume hood at 22 °C.  Samples were mounted and coated with 2.5 nm of 
platinum/palladium (Hummer Sputtering System, Union City, CA) and imaged with a Hitachi S-
4700 cold-field emission scanning electron microscope (FE-SEM; Tustin, CA) with an 
accelerating voltage of 5 kV. 
6.3. Results and discussion  
6.3.1. Materials characterization 
The BET specific surface area (SSA) of ???? and ???? are 1221 and 560 m2/g, 
respectively.  ???? represents the lowest BET surface area of 315 m2/g.  Pore size distributions 
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of three materials calculated by NLDFT are shown in Figure 6.2.  The pore textural 
characteristics, including BET SSA, external SSA, and total pore volume are provided in Table 
6.1.  ???? and ?????possess the median mesopore width of 36 and 70 Å with a total pore 
volume of around 0.9 and 0.55 ml/g, respectively.  To visualize the presence of micropore 
distributions present in these samples, we employed CO2 adsorption isotherms, and the pore size 
distribution plot is inserted as an inset in Figure 6.2. 
 
Table 6.1.  Pore textural properties of mesoporous carbons samples 
Carbon 
species 
BET SSA 
(m2/g) 
External SSA 
(m2/g)a 
Total Pore 
Volume (cm3/g)b 
????? 1221 399 0.90 
????? 560 322 0.60 
????? 315 244 0.55 
a Calculated by statistical thickness (?-plot) method. b Calculated by NLDFT method. 
 
?
Figure 6.2.  Pore size distributions of ????, ????, and ????.  (Inset) Micropore distribution of 
the mesoporous carbon samples calculated from CO2 adsorption isotherm at 273 K; pore width is 
in log scale. 
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???? shows a higher mesopore width at 70 Å with a lower mesopore volume of 0.55 
ml/g.  TEM images (Figure 6.3 A, C, E) of these mesoporous carbons did not reveal a 
geometrical order of pores; instead it demonstrated a ‘worm-like’ porous entity in the carbon 
matrix.  SEM images (Figure 6.3 B, D, F) showed that all the mesoporous carbon particles are 
highly irregular in external morphology.  
We performed EDXS studies to get the elemental analysis of the carbon samples, and 
the results are shown in Table 6.2.  The carbon content varies within 80-87 % along with a large 
proportion of oxygen, 12-19 %.  The origin of oxygen can be rooted to the hydroxyl groups in the 
carbon precursors that might have converted to other carbon containing functional groups during 
chemical reaction and carbonization. Slightly lower oxygen content in ???? can most likely be 
attributed to the reheating of the carbon sample during activation, which might have caused 
cleavage of oxygen-containing functional groups.  Presence of oxygen in metallic oxides, possibly 
arrived from porcelain boats in the course of carbonization, may also contribute to total oxygen 
content, although such contribution is much smaller compared to the surface functionality. 
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Figure 6.3.  Electron microscopic images of mesoporous carbon samples.  (A) TEM and (B) SEM 
images of ????; (C) TEM and (D) SEM images of ????; (E) TEM and (F) SEM images of ????. 
   
Table 6.2.  Elemental analysis of mesoporous carbons samples 
Carbon 
species?
Carbon?
(%) 
Oxygen?
(%) 
Potassium?
(%) 
Others?
(%) 
????? 87.06? 12.04? 0.76? 0.14?
????? 79.59? 19.77? 0.03? 0.61?
????? 80.76? 18.76? 0.01? 0.47?
?
?
A B 
C D 
E F 
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???? also has a higher percentage of potassium (0.76%) compared to the rest of the 
carbon samples, and that can definitely be attributed to the activation with KOH.  All the 
mesoporous carbon samples contain a very small fraction of nitrogen and trace elements (0.14-
0.47 % aluminium, zirconium, calcium, and magnesium) that might have originated from the 
porcelain boat in the course of carbonization or from an impurity in the precursor chemicals. 
6.3.2. In vitro cell interactions 
In vitro biocompability and toxicity tests are the prerequisites for any biomaterials prior to 
in vivo animal model evaluation and clinical trials [2, 12].  Mesoporous carbon toxicity was 
examined in HeLa cells with an MTT cell viability assay.  The MTT assay is a common method 
employed to measure the biochemical activity of cells seeded on carbon materials [37, 38].  
Figure 6.4 shows the results of cytotoxicity studies of the mesoporous carbons; none of the 
carbon samples demonstrated acute cytotoxicity.  ???? and ???? demonstrated negligible 
toxicity in the range of 50 μg/ml to 500 μg/ml (survival >90%).  ???? showed slight toxicity with 
cell survival decreasing with an increase in concentration and demonstrated around 70% survival 
at the highest concentration tested (500 μg/ml).  The concentration-dependent cell survival of the 
mesoporous carbon materials are higher than the nanosized mesoporous carbon reported by 
Fang et al.[33] in which cell survival was not more than 60% at a much lower carbon 
concentration of 100 μg/ml with a shorter incubation period of 24 h.  A closer inspection of our 
result can reveal a definite pattern of cytotoxicity, that is, it increases with the increase in surface 
area of the carbon materials tested (????<????<????) at all concentrations.  In fact, such 
dependence of cytotoxicity is quite prevalent not only in the case of porous carbon materials [23], 
but also for mesoporous silicas [39, 40]. 
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Figure 6.4.  Cytotoxicity of mesoporous carbon samples in HeLa cells.  Cells were incubated with 
mesoporous carbon materials for 5 days, followed by evaluation of cell viability with an MTT 
Assay.  Percent survival is defined in Eq. 6.1.  All data points are the average of three separate 
experiments and the error bars represent the standard deviation. 
 
The so-called cytotoxicity at the higher carbon concentration may be attributed to the 
simple reason of physical hindrance to the cell proliferation [22]; however, the patterned toxicity 
may need different sets of explanations.  Unlike nanosized carbons, the cellular uptake of the 
carbon matrix can definitely be ruled out for any of our samples.  Although external morphologies, 
including shapes and size of porous matrix, were counted as plausible credential for porous silica 
towards cytoxocity [39], the mesoporous carbon samples tested in this study are highly irregular 
in shape and, most likely, a shape factor did not contribute towards toxicity.  A closer inspection 
suggests the size of ???? and ???? are in the order of 20-50 μm in size whereas ???? particles 
are larger than 100 μm.  Smaller particles may interact better with the HeLa cell (size ~ 14 μm) 
providing a stronger obstruction towards their proliferation.  It is also noteworthy that the external 
surface areas are in the exact order of cytotoxicity (????>????>????) and the higher external 
surface area also possesses a greater chance of more intimate interactions with cellular bodies. 
Surface chemistry is another significant factor that may corroborate the patterned toxicity. 
Although ???? has a higher concentration of potassium, the literature does not provide any 
evidence that potassium causes cytotoxicity.  ???? has the lowest concentration of oxygen 
(Table 6.2), which essentially means it has lower percent of oxygen-containing functional groups 
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and possesses the highest carbon content.  As the oxygen-containing functional groups may 
have greater change for providing higher degree of hydrophilicity on the hydrophobic carbon 
surface, ???? could be more hydrophobic than rest of the samples.  It is mentioned in the 
literature [41] that a hydrophilic surface can interact with a protein surface through an 
intermediate layer of water molecules, whereas a hydrophobic surface possesses a higher 
chance of directly interacting with such proteins.  This direct interaction could cause denaturation 
and conformational changes of the proteins.  One known effect of hydrophobic surface interaction 
with cells has been shown to lead to the adverse effects of adenosine triphosphate (ATP) 
depletion and triggering of cell apoptosis [42].  It is also suggested that a hydrophobic surface 
itself may provide a higher risk of cell apoptosis [43].  Although the higher toxicity of ???? can be 
attributed to its hydrophobic nature, such interactions may not be supportive to distinguish the 
cytotoxic behavior between ???? and ????? as both of them possess similar oxygen content and 
apparently the same hydrophobic/hydrophilic nature. 
Earlier it was suggested that a material with high external surface area could be less 
favorable as a biomaterial owing to its higher cytotoxicity [44].  Our results demonstrated that the 
internal or the BET surface area could be the most intriguing factor towards explaining the 
cytotoxicity pattern.  Earlier, it was reported that silica could be responsible for generating the 
reactive oxygen species (ROS) radicals that cause cell damage [45].  Yet, the precise role of 
surface area as a catalytic agent in such phenomena was neither properly understood nor 
thoroughly investigated.  We hypothesize that another indirect phenomena may also be 
responsible towards this effect.  We suggest that a higher surface area material can inherently 
adsorb larger amount of nutrients within its porous moiety from the proximity or in contact with the 
cellular bodies, and therefore, the cells may die because of lack of nutrients to survive.  Such 
phenomena, if true, can support the patterned cytotoxic behavior.  However, more rigorous 
experiments with varying conditions, which are not within the scope of this work, are required to 
experimentally validate this hypothesis.  Nevertheless, the overall experimental work suggests 
that mesoporous carbon samples demonstrated minimal cytotoxic nature and are benign, similar 
to other ???????? carbons [46]. 
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To investigate cell viability, we incubated the mesoporous carbon samples were with 
fibroblast cells from 1-4 days, along with the mock media as a control substrate for comparison.  
The concentration of carbons samples employed was 100 μg/ml.  The results of this study 
indicate that cell viability was very high and almost constant (>98%) from day 1 to day 3 without 
any significant difference with the mock media (Figure 6.5A).  After the third day, cell viability 
decreased (~82%) for all the mesoporous carbon samples tested, including the mock media.  The 
number of fibroblast cells also decreased after the third day for all the samples and the mock 
media (Figure 6.5B). 
?
Figure 6.5.  Biocompatibility of mesoporous carbon samples in fibroblast cells.  (A) Percent 
viability and (B) cell number.  Cells were incubated with mesoporous carbon materials from 1 to 4 
days.  Cell viability was measured with a trypan blue exclusion assay.  Percent viability is defined 
in Eq. 6.2.  All data points are the average of three separate experiments; error bars represent 
the standard deviation. 
 
The cause of the decreasing trend in cell populations can certainly be ascribed to the lack 
of nutrients in the culture medium without any possible influence of the mesoporous carbons.  
The cells likely needed fresh media with nutrients after the third day of culture, but it was not 
possible to replenish with fresh nutrients in the course of experiments owing to the atypical nature 
of dispersed mesoporous carbons in culture media.  It is also noteworthy to mention that the cell 
viability assay did not reveal a patterned behavior with mesoporous carbons, and it essentially 
confirms that the cell viability is independent of porosity, size and shape of such materials. 
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We have analyzed the growth of fibroblast cells on mesoporous carbon samples with FE-
SEM for visual inspection purposes (Figure 6.6).  All the mesoporous carbon samples were 
incubated with fibroblast cells for 3 days.  We found that the fibroblast cells surrounded the 
carbon particles, suggesting that the carbon surface did not offer adverse effects to the 
proliferation of cells.   
?
Figure 6.6.  Fibroblast cell growth on mesoporous carbon samples.  (A and B) ???1, (C and D) 
????, and (E and F) ????.  Cells were incubated with carbon samples for 3 days.  Scale bars 
are (top) 50 and (bottom) 20 ?m. 
?
Although all three varieties of carbon provided good platforms for fibroblast cell growth, 
???? appeared to demonstrate a better contact and adhesion surface for the cells, as shown in 
Figure 6.6 E&F.  Apparently, better cell compatibility of ???? is in agreement with its highest cell 
survival with HeLa cells, but it did not provide a similar trend with fibroblast cell viability and cell 
number (Figure 6.5 A&B), suggesting that cell contact has a minimal influence in the viability 
assay.  The better adhesion properties of ???? may be attributed to the lower porosity of the 
material providing better “anchoring”, higher hydrophilic surface, or better transport of nutrients 
through the larger pores of the ???? material. 
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6.3.3. Hemocompatibility of mesoporous carbon materials 
The hemocomapatibility of a drug carrier is the prerequisite for intravascular drug 
delivery.  In our study, we employed two hemocomapatibility tests: hemolysis and adsorption of 
blood plasma proteins.  Hemolysis studies determine the stability of red blood cell (RBC) in 
contact with a foreign body. Four concentrations of mesoporous carbons ranging from 100-500 
μg/ml were employed to examine the hemolysis. The results are shown in Table 6.3. ?
Table 6.3.  Hemolysis (%) caused by mesoporous carbon samplesa 
Carbon 
species?
100 ?g/ml?
(%)?
200 ?g/ml?
(%)?
300 ?g/ml?
(%)?
500 ?g/ml?
(%)?
????? 0.18 ± 0.32? 0.36 ± 0.29? 0.79 ± 0.35? 0.71 ± 0.24?
????? 0.13 ± 0.04? 0.33 ± 0.12? 0.43 ± 0.12? 0.63 ± 0.04?
????? 0.25 ± 0.04? 0.15 ± 0.20? 0.30 ± 0.27? 0.76 ± 0.66?
a The standard deviation is calculated from three samples  
?
Primary observations suggest that the hemolysis is minimum (< 1%) for all samples at all 
concentrations.  Although the majority of the data represented demonstrated slight enhancement 
of hemolysis with an increase in carbon concentration from 100 to 500 μg/ml, we did not find 
ubiquity of such behavior.  Additionally, the relationship of hemolysis with different samples (i.e., 
surface area and particle size) did not reveal any patterned behavior.  Such behavior is 
completely in disagreement with previous studies with mesoporous and nanosized silica particle, 
where hemolysis was proved to be a strong function of porosity, shape and size [47-49].  
Comparison of hemolysis data with mesoporous silica suggests that silica can cause hemolysis 
as high as 20-80 %[47, 48] at the highest concentration of study (500 μg/ml), these results are 
orders of magnitude higher than our results.  Although the mesoporous carbon employed in our 
study was not nanosized and it may appear that the size effect was not investigated, Zhao et 
al.[49] confirmed that the smaller particles, in fact, can potentially be safe towards RBC as they 
get adsorbed on the RBC surface without disturbing the cell membrane or morphology.  Based on 
this finding, we can draw a hypothesis that nanosized mesoporous carbon may possess an even 
lesser threat towards intravascular drug delivery.  This suggests that mesoporous carbon material 
can serve as a better choice over mesoporous silica for intravascular drug delivery. 
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The amount of plasma protein adsorption onto biomaterials is an important parameter 
towards its biocompatibility in terms of implants, intravascular delivery and tissue engineering.  
When a foreign body comes in contact with the bloodstream, the surface could be rapidly covered 
with plasma protein, often termed the protein corona [50, 51].  Although in rare occasions where 
fibronectin adsorption has facilitated cell attachment [52, 53], nonspecific adsorption of proteins 
onto the biomaterial surface is mostly undesirable as it may trigger adverse effects, such as 
localized inflammation, hyperactive immune response, or conformational changes of protein 
structure leading to loss of activity[54] and thrombolysis [55, 56].  Here, we have studied the 
nonspecific adsorption of two plasma proteins: bovine serum albumin (BSA) and bovine serum 
fibrinogen (FIB).  Table 6.4 shows the results of protein adsorption.  
Table 6.4.  Protein adsorption on mesoporous carbon samplesa 
Carbon 
species 
BSA adsorption 
(g of protein/m2 of carbon) x 10-4 
FIB adsorption 
(g of protein/m2 of carbon) x 10-4 
????? 2.21 ± 0.31 25.5  ± 3.48 
????? 3.01 ± 0.03 38.1  ± 0.93 
????? 6.08 ± 1.72 48.8  ± 1.82 
a The standard deviation is calculated from three samples 
?
As BET SSA encompasses a large portion of narrow micropore surfaces that may not 
take part in larger protein adsorption, we employed external SSA (Table 6.1) for calculating 
protein-binding capacity.  We found that BSA adsorption was < 1 mg/m2 of carbon surface, 
whereas fibrinogen adsorption was 1 order of magnitude higher, 2-4 mg/m2.  
The BSA adsorption capacity was in line with the overall protein adsorption onto other 
porous biomaterials, like hydroxyapatite, zirconia and alumina [55].  A comparison of BSA 
adsorption on mesoporous carbon samples (1-2 nmol protein/mg carbon) with human serum 
albumin (HSA) adsorption onto mesoporous silica nanoparticles (MSN [56]; 3-7 nmol protein/mg 
MSN) suggests that the carbon surface provides less affinity towards albumin.  Although 
fibrinogen adsorption was higher (more than 3 nmol protein/mg carbon), we could not compare its 
adsorption with other porous biomaterials owing to the lack of reported data.  Slightly higher 
affinity towards fibrinogen may result in somewhat higher risk of thrombolysis, but as suggested 
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in the literature, functionalization or covering the surface with biocompatible PEG molecules will 
reduce such risk [57]. 
To estimate the percent monolayer coverage, we employed a closed packing hard-
sphere model of adsorbed proteins.  The monolayer model suggests a surface density of 4.8 and 
8.5 mg/m2 for BSA and FIB, respectively.  On the basis of these surface densities, we estimated 
that BSA covered 4.5, 6.1 and 12.4 % of ????, ???? and ????, respectively, whereas FIB 
possesses the higher surface coverage of 26.5, 43.2 and 57.9% for ????, ???? and ??????
respectively.  Although the ideal hard sphere model can be deviated in terms of ??? uncoiling or 
flattening of the protein molecule in proximity to adsorption surfaces [58, 59] and ??? nonspecific 
and undesirable locations of calculated external surfaced area, the coverage percent can provide 
an approximation of surface occupancies by protein molecules. 
A clear pattern of protein adsorption onto mesoporous carbons can be deduced.  For 
both types of proteins, the adsorption capacity increases in the order of ????<????<????.  It is 
observed that fibrinogen adsorption is 1 order of magnitude higher for all three types of carbons.  
Although the higher protein adsorption to ???? and ???? can be related to the higher oxygen 
content resulting in a greater number of hydrogen bonds, such an explanation does not fully 
support the trend in loading amounts.  The explanations for higher fibrinogen binding and 
patterned relation between binding capacity and materials properties definitely require much 
detailed research and understanding of carbon surface, including precise functionality 
characterization, hydrophobicity/hydrophilicity and Z-potential determination, which are beyond 
the scope of this work.  Nonetheless, the protein adsorption data suggests that the carbon 
surface is mostly biocompatible and similar to the other biomaterials??
6.4. Conclusions 
In this work, we have studied the in vitro biocompatibility of soft-templated mesoporous 
carbons by cytotoxicity experiments with HeLa cells, cell viability with fibroblast cells and blood 
compatibility with hemolysis and protein adsorption.  ???? and ???? samples showed minimal 
cytotoxicity while ???? demonstrated only slight toxicity within the concentrations of 50-500 
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μg/ml.  Cell growth assays with fibroblast cells demonstrated a constant viability at a 
concentration of 100 μg/ml of mesoporous carbons and a clear visual observation of cell-carbon 
contact was confirmed.  None of the carbon samples demonstrated hemolysis (<1 %).  Protein 
adsorption with bovine serum albumin (BSA) and fibrinogen demonstrated lower protein binding 
with a decreasing trend with an increase in carbon surface area.  All the results suggested that 
the mesoporous carbon materials are biocompatible and, the degree of biocompatibility is within 
the range or higher than other biomaterials currently employed in biomedical applications.
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Chapter 7  
Conclusions and future work  
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7.1. Conclusions 
In this dissertation, we discovered that osmolytes function as antiviral compounds against 
viruses and as flocculants in order to improve virus purification methods for vaccine production.  
We also demonstrated that soft-templated mesoporous carbons are biocompatible and not toxic 
for mammalian cells.  Future work on these materials will determine if they can be used as 
vehicles for vaccine delivery. 
We have discovered that two protecting osmolytes, trimethylamine N-oxide (TMAO) and 
glycine at 0.2 M reduce the infectivity of porcine parvovirus (PPV), a non-enveloped virus, by 4 
LRV (99.99%), likely by disruption of capsid assembly [1].  These results are of great interest, 
since to our knowledge, the majority of synthetic and natural compounds that have been found 
are for enveloped viruses, and not for non-enveloped viruses.  The majority of these antiviral 
compounds found in the literature inhibit virus attachment, and they are able to do this by 
inactivating the virus envelope (see Chapter 2).  TMAO and glycine showed antiviral activity after 
being added 20 h post-infection, indicating that they could be used after the virus has infected the 
cells, indicating that they could be used after the virus has infected the cells.  This increases their 
potential to be used as therapeutic drugs.   
We also found that osmolytes could be used as flocculants for virus purification, and 
overcomes many of the limitations of current purification methods, such as chromatography and 
nanofiltration.  Osmolytes are able to specifically flocculate hydrophobic virus particles by 
depleting a hydration layer around the particles and subsequently cause virus aggregation.  The 
best flocculants for PPV, were found to be glycine, alanine, sucrose, trehalose and mannitol [2]; 
and the best flocculants for the enveloped Sindbis virus (SVHR) were proline, betaine, sucrose, 
trehalose, raffinose, and mannitol.  These osmolytes demonstrate a high removal (>80%) of virus 
with a 0.2 ?m filter, which is usually used to remove bacteria, not small viruses such as PPV and 
SVHR.  A micro-filter increases the flux and decreases the transmembrane pressure of typical 
virus filters.  We were able to preferentially flocculate PPV and SVHR while leaving model 
proteins in solution.  Protein removal was very low with osmolytes (< 20%) as compared to the 
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salts (55% for BSA and 87% for lysozyme).  Salts, and not osmolytes were able to enhance 
protein flocculation, whereas both were able to flocculate virus particles.  The aim in this project 
was to find an osmolyte that could be used as platform purification for viral products.  Mannitol at 
0.3 M was able to demonstrate a high virus removal, 81% for PPV [2] and 98.1% for SVHR.  
Virus flocculation with mannitol, followed by microfiltation could be used as a platform process for 
virus purification.  
One of the biggest challenges in vaccine technology is to develop vaccines that are safe 
and offer a strong immune response to patients [3].  Conventional vaccines offer effective 
immune response but they offer reactogenic effects.  New vaccine technologies have been able 
to mitigate these effects, but often with the cost of reduced effective immune response.  Vaccine 
delivery vehicles, which can target the immune cells with adequate doses, have been suggested 
for improving the immune response.  In this study, we proposed soft-templated mesoporous 
carbon as a new type of vaccine delivery vehicle.  In this study, soft-templated mesoporous 
carbon materials showed minimal toxicity and high cell viability with mammalian cells.  
Hemocompatibility studies show a <1% of hemolysis and low adsorption of blood proteins to 
mesoporous carbon materials.  The results showed that our soft-templated mesoporous carbon 
materials are biocompatible, and the degree of biocompatibility is within the range or higher than 
other biomaterials currently used in biomedical applications [4]. 
7.2. Future work 
For antiviral compounds, we would like to explore the antiviral properties of fruits rich in 
polyphenols.  Many studies have demonstrated antiviral properties of different types of fruits 
against non-enveloped viruses [5-14].  However, the active compounds have not been isolated 
yet.  Tea and other plant polyphenols have demonstrated antiviral activity with enveloped viruses 
[15-21].  We believe we can find antiviral properties of specific polyphenols found in fruits against 
non-enveloped viruses, such as the rhinovirus, which cause the common cold in humans, and 
hepatitis A virus.  The aim in this research area is to find natural compounds that can inhibit virus 
infectivity without causing severe effects in the cells.  Fruits are known to be healthy and are used 
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for consumption, so we believe they are of great interest.  With the knowledge that our lab has in 
virology assays, we hope to find new therapeutic antiviral compounds for non-enveloped viruses 
that affect humans.  
The aim of virus flocculation with osmolytes followed by microfiltration is to replace 
current unit operations used in virus purification, such as chromatography and nanofiltration.  In 
order to validate this method for virus purification, the virus needs to be recovered from the 
membrane surface.  We have recovered infectious virus particles from the membrane surface, 
but the recovery is currently low (~2%).  We are exploring new methods to recovery the virus, 
such as the possibility of using a diafiltration setup.  Diafiltration is a technique that has been 
used before to concentrate virus particles and has led to high recoveries of virus [22, 23].  It can 
enhance the product yield, along with recycling the osmolyte solution.  Further studies will need to 
be done in order to determine the best filtration system, the filter capacity and the pressure-flux 
profiles for successfully commercialization of virus flocculation in osmolytes. 
We are also interested in trying virus flocculation in osmolytes with different types of membrane 
materials in our filtration step.  In our lab, we have been able to created functionalized nanofibers, 
which have shown 2-4 logs reduction of PPV and SVHR [24, 25].  We would like to make our own 
membranes based on functionalized nanofibers and used these membranes after virus 
flocculation in osmolytes in order to enhance the virus removal.  We would also like to try a 
double effect of flocculants.  We can try different combinations of our top osmolytes to enhance 
virus removal.  With the best combination of osmolytes flocculants, we could try different times of 
flocculation and reduce our current incubation time, which is 2 hours.  Kinetics studies could help 
us to understand how fast is the aggregation process and how different conditions (i.e. 
temperature, flocculants, pH) could affect the speed of the aggregation process. 
For our collaborative research project, we are planning to perform other types of cell 
viability and cytotoxicity assay to make our hypothesis stronger.  We have assessed cell viability 
with a trypan blue assay, where trypan blue stains dead cells, which can be counted using a 
hemocytometer under a microscope.  However, trypan blue is a cell exclusion assay.  Cells that 
are alive, but have a reduced function, are counted equally as cells that are alive and healthy.  At 
160 
?
the same time, it can stain cells whose membranes are temporarily permeable, wrongly 
identifying them as dead [26].  The cytotoxicity assay that we use, the MTT Assay, is a well-
known cell-viability assay that measures mitochondrial activity in living cells.  This MTT Assay 
only indicates if cells are dead or alive.  Since we are more interested in cell metabolism 
functions, we are planning to measure the concentration dependent adenosine triphosphate 
(ATP) depletion of cell and the concentration dependent reactive oxygen species (ROS) of new 
soft-templated mesoporous carbon materials.  ATP is the energy currency of the cells, is in 
charge of transporting energy within the cells for several metabolic functions.  ATP depletion is 
associated with toxicity, and can cause cell damage and apoptosis [27].  ROS are reacting 
molecules containing oxygen, they are produced during normal metabolism and are involved in 
several cellular functions, such as cell proliferation, differentiation and apoptosis [28, 29].  ROS 
are produced inside of the human body and removed by antioxidants [30], since high 
concentrations of ROS can be toxic to the cells [29].  The positive results that we expect to get 
from the ATP and ROS studies will make our biocompatibility studies stronger.  With the hope of 
finding positives results in our ???????? assays, we hope to move to ??????? assays.?  
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Notice of such denial will be made using the contact information provided by you. Failure to 
receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright 
Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as 
a result of a denial of your permission request, other than a refund of amount(s) paid by you to 
Elsevier and/or Copyright Clearance Center for denied permissions. 
 
LIMITED LICENSE 
 
The following terms and conditions apply only to specific license types: 
 
15. Translation: This permission is granted for non-exclusive world English rights only unless 
your license was granted for translation rights. If you licensed translation rights you may only 
translate this content into the languages you requested. A professional translator must perform all 
translations and reproduce the content word for word preserving the integrity of the article. If this 
license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all 
languages. 
 
16. Posting licensed content on any Website: The following terms and conditions apply as 
follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright information line on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a scanned 
version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu. Licensing material from an Elsevier book: A hyper-text link must be included to 
the Elsevier homepage at http://www.elsevier.com. All content posted to the web site must 
maintain the copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide 
students registered on a relevant course. This permission is granted for 1 year only. You may 
obtain a new license for future website posting. 
For journal authors: the following clauses are applicable in addition to the above: Permission 
granted is limited to the author accepted manuscript version* of your paper. 
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*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
author’s version of the manuscript of an article that has been accepted for publication and which 
may include any author-incorporated changes suggested through the processes of submission 
processing, peer review, and editor-author communications. AAMs do not include other publisher 
value-added contributions such as copy-editing, formatting, technical enhancements and (if 
relevant) pagination. 
 
You are not allowed to download and post the published journal article (whether PDF or HTML, 
proof or final version), nor may you scan the printed edition to create an electronic version. A 
hyper-text must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal production process, 
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ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object 
Identifier (DOI). This number provides the electronic link to the published article and should be 
included in the posting of your personal version. We ask that you wait until you receive this e-mail 
and have the DOI to do any posting. 
 
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional 
repository for internal use only and may make their manuscript publically available after the 
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18. For book authors the following clauses are applicable in addition to the above: Authors are 
permitted to place a brief summary of their work online only.. You are not allowed to download 
and post the published electronic version of your chapter, nor may you scan the printed edition to 
create an electronic version. Posting to a repository: Authors are permitted to post a summary of 
their chapter only in their institution’s repository. 
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submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the 
Library and Archives of Canada to supply single copies, on demand, of the complete thesis and 
include permission for UMI to supply single copies, on demand, of the complete thesis. Should 
your thesis be published commercially, please reapply for permission. 
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Elsevier publishes Open Access articles in both its Open Access journals and via its Open 
Access articles option in subscription journals. 
 
Authors publishing in an Open Access journal or who choose to make their article Open Access 
in an Elsevier subscription journal select one of the following Creative Commons user licenses, 
which define how a reader may reuse their work: Creative Commons Attribution License (CC BY), 
Creative Commons Attribution – Non Commercial -ShareAlike (CC BY NC SA) and Creative 
Commons Attribution – Non Commercial – No Derivatives (CC BY NC ND) 
 
Terms & Conditions applicable to all Elsevier Open Access articles: 
 
Any reuse of the article must not represent the author as endorsing the adaptation of the article 
nor should the article be modified in such a way as to damage the author’s honour or reputation. 
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If any part of the material to be used (for example, figures) has appeared in our publication with 
credit or acknowledgement to another source it is the responsibility of the user to ensure their 
reuse complies with the terms and conditions determined by the rights holder. 
 
Additional Terms & Conditions applicable to each Creative Commons user license: 
 
CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), to include in 
a collective work (such as an anthology), to text or data mine the article, including for commercial 
purposes without permission from Elsevier 
 
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create 
extracts, abstracts and other revised versions, adaptations or derivative works of or from an 
article (such as a translation), to include in a collective work (such as an anthology), to text and 
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CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include 
it in a collective work (such as an anthology), provided you do not alter or modify the article, 
without permission from Elsevier 
 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND 
license requires permission from Elsevier and will be subject to a fee. 
 
Commercial reuse includes: 
 
v1.6 
 
· Promotional purposes (advertising or marketing) 
 
· Commercial exploitation ( e.g. a product for sale or loan) 
 
· Systematic distribution (for a fee or free of charge) 
 
Please refer to Elsevier's Open Access Policy for further information. 
 
21. Other Conditions: 
 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-
646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
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provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a 
timely basis, then any license preliminarily granted shall be deemed automatically revoked and 
shall be void as if never granted. Further, in the event that you breach any of these terms and 
conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically 
revoked and shall be void as if never granted. Use of materials as described in a revoked license, 
as well as any use of the materials beyond the scope of an unrevoked license, may constitute 
copyright infringement and publisher reserves the right to take any and all action to protect its 
copyright in the materials. 
 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 
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out of your use of the licensed material other than as specifically authorized pursuant to this 
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12. No Amendment Except in Writing: This license may not be amended except in a writing 
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your obligations established by these terms and conditions and those established by CCC's 
Billing and Payment terms and conditions, these terms and conditions shall control. 
 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in 
this License at their sole discretion, for any reason or no reason, with a full refund payable to you. 
Notice of such denial will be made using the contact information provided by you. Failure to 
receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright 
Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as 
a result of a denial of your permission request, other than a refund of amount(s) paid by you to 
Elsevier and/or Copyright Clearance Center for denied permissions. 
 
LIMITED LICENSE 
 
The following terms and conditions apply only to specific license types: 
 
15. Translation: This permission is granted for non-exclusive world English rights only unless 
your license was granted for translation rights. If you licensed translation rights you may only 
translate this content into the languages you requested. A professional translator must perform all 
translations and reproduce the content word for word preserving the integrity of the article. If this 
license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all 
languages. 
 
16. Posting licensed content on any Website: The following terms and conditions apply as 
follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright information line on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a scanned 
version of the material to be stored in a central repository such as that provided by 
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the Elsevier homepage at http://www.elsevier.com. All content posted to the web site must 
maintain the copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide 
students registered on a relevant course. This permission is granted for 1 year only. You may 
obtain a new license for future website posting. 
For journal authors: the following clauses are applicable in addition to the above: Permission 
granted is limited to the author accepted manuscript version* of your paper. 
179 
?
?
 
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
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repository for internal use only and may make their manuscript publically available after the 
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18. For book authors the following clauses are applicable in addition to the above: Authors are 
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Creative Commons Attribution – Non Commercial -ShareAlike (CC BY NC SA) and Creative 
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Terms & Conditions applicable to all Elsevier Open Access articles: 
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The author(s) must be appropriately credited. 
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this transaction (along with the Billing and Payment terms and conditions established by 
Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account 
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GENERAL TERMS 
 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the 
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“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, 
Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY 
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Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier.” 
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hereby given. 
 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
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any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please 
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you have disclosed complete and accurate details of your proposed use, no license is finally 
effective unless and until full payment is received from you (either by publisher or by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a 
timely basis, then any license preliminarily granted shall be deemed automatically revoked and 
shall be void as if never granted. Further, in the event that you breach any of these terms and 
conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically 
revoked and shall be void as if never granted. Use of materials as described in a revoked license, 
as well as any use of the materials beyond the scope of an unrevoked license, may constitute 
copyright infringement and publisher reserves the right to take any and all action to protect its 
copyright in the materials. 
 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
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10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 
respective officers, directors, employees and agents, from and against any and all claims arising 
out of your use of the licensed material other than as specifically authorized pursuant to this 
license. 
 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
 
12. No Amendment Except in Writing: This license may not be amended except in a writing 
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, which 
terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and 
conditions. These terms and conditions, together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein), comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction. In the event of any conflict between 
your obligations established by these terms and conditions and those established by CCC's 
Billing and Payment terms and conditions, these terms and conditions shall control. 
 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in 
this License at their sole discretion, for any reason or no reason, with a full refund payable to you. 
Notice of such denial will be made using the contact information provided by you. Failure to 
receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright 
Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as 
a result of a denial of your permission request, other than a refund of amount(s) paid by you to 
Elsevier and/or Copyright Clearance Center for denied permissions. 
 
LIMITED LICENSE 
 
The following terms and conditions apply only to specific license types: 
 
15. Translation: This permission is granted for non-exclusive world English rights only unless 
your license was granted for translation rights. If you licensed translation rights you may only 
translate this content into the languages you requested. A professional translator must perform all 
translations and reproduce the content word for word preserving the integrity of the article. If this 
license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all 
languages. 
 
16. Posting licensed content on any Website: The following terms and conditions apply as 
follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright information line on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a scanned 
version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu. Licensing material from an Elsevier book: A hyper-text link must be included to 
the Elsevier homepage at http://www.elsevier.com. All content posted to the web site must 
maintain the copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide 
students registered on a relevant course. This permission is granted for 1 year only. You may 
obtain a new license for future website posting. 
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For journal authors: the following clauses are applicable in addition to the above: Permission 
granted is limited to the author accepted manuscript version* of your paper. 
 
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
author’s version of the manuscript of an article that has been accepted for publication and which 
may include any author-incorporated changes suggested through the processes of submission 
processing, peer review, and editor-author communications. AAMs do not include other publisher 
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Identifier (DOI). This number provides the electronic link to the published article and should be 
included in the posting of your personal version. We ask that you wait until you receive this e-mail 
and have the DOI to do any posting. 
 
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional 
repository for internal use only and may make their manuscript publically available after the 
journal-specific embargo period has ended. 
 
Please also refer to Elsevier's Article Posting Policy for further information. 
 
18. For book authors the following clauses are applicable in addition to the above: Authors are 
permitted to place a brief summary of their work online only.. You are not allowed to download 
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